[S02DA03, antipyrine, The risk or severity of hypertension can be increased when Flupentixol is combined with Antipyrine.]
[L01AD04, streptozocin, The risk or severity of myelosuppression can be increased when Flupentixol is combined with Streptozocin.]
[M03AB01, succinylcholine, Succinylcholine may increase the central nervous system depressant (CNS depressant) activities of Flupentixol.]
[J01EC01, sulfamethoxazole, The risk or severity of QTc prolongation can be increased when Sulfamethoxazole is combined with Flupentixol.]
[S01AB02, sulfisoxazole, The risk or severity of QTc prolongation can be increased when Sulfisoxazole is combined with Flupentixol.]
[M01AB02, sulindac, The risk or severity of hypertension can be increased when Sulindac is combined with Flupentixol.]
[N05AL01, sulpiride, Flupentixol may increase the antipsychotic activities of Sulpiride.]
[N03AX03, sulthiame, Sulthiame may increase the central nervous system depressant (CNS depressant) activities of Flupentixol.]
[M01AX04, apazone, The risk or severity of hypertension can be increased when Flupentixol is combined with Azapropazone.]
[L01BB02, mercaptopurine, The risk or severity of myelosuppression can be increased when Flupentixol is combined with Mercaptopurine.]
[L02BA01, tamoxifen, The risk or severity of QTc prolongation can be increased when Tamoxifen is combined with Flupentixol.]
[N05CD07, temazepam, Flupentixol may increase the sedative activities of Temazepam.]
[L01CB02, teniposide, The risk or severity of myelosuppression can be increased when Flupentixol is combined with Teniposide.]
[R03CC03, terbutaline, The therapeutic efficacy of Terbutaline can be decreased when used in combination with Flupentixol.]
[N07XX06, tetrabenazine, The risk or severity of QTc prolongation can be increased when Tetrabenazine is combined with Flupentixol.]
[S01HA03, tetracaine, Tetracaine may increase the central nervous system depressant (CNS depressant) activities of Flupentixol.]
[N05AE05, lurasidone, Flupentixol may increase the hypotensive activities of Lurasidone.]
[A04AD10, dronabinol, Dronabinol may increase the central nervous system depressant (CNS depressant) activities of Flupentixol.]
[N04BC07, apomorphine, The therapeutic efficacy of Apomorphine can be decreased when used in combination with Flupentixol.]
[L04AX02, thalidomide, Flupentixol may increase the central nervous system depressant (CNS depressant) activities of Thalidomide.]
[L01XX41, eribulin, The risk or severity of myelosuppression can be increased when Flupentixol is combined with Eribulin.]
[R06AD03, thiethylperazine, Thiethylperazine may increase the central nervous system depressant (CNS depressant) activities of Flupentixol.]
[L01AC01, thiotepa, The risk or severity of myelosuppression can be increased when Flupentixol is combined with Thiotepa.]
[L01BB03, thioguanine, The risk or severity of myelosuppression can be increased when Flupentixol is combined with Tioguanine.]
[N05CA19, thiopental, Flupentixol may increase the sedative activities of Thiopental.]
[N05AB08, thioproperazine, Flupentixol may increase the orthostatic hypotensive, hypotensive, and antihypertensive activities of Thioproperazine.]
[N05AC02, thioridazine, The risk or severity of QTc prolongation can be increased when Thioridazine is combined with Flupentixol.]
[N05AF04, thiothixene, Thiothixene may increase the central nervous system depressant (CNS depressant) activities of Flupentixol.]
[G04BE06, moxisylyte, The risk or severity of hypertension can be increased when Flupentixol is combined with Moxisylyte.]
[N05AL03, tiapride, Tiapride may increase the central nervous system depressant (CNS depressant) activities of Flupentixol.]
[N02AX01, tilidine, Tilidine may increase the central nervous system depressant (CNS depressant) activities of Flupentixol.]
[S01ED01, timolol, Timolol may increase the orthostatic hypotensive activities of Flupentixol.]
[M02AX02, tolazoline, Tolazoline may increase the orthostatic hypotensive, hypotensive, and antihypertensive activities of Flupentixol.]
[M02AA21, tolmetin, The risk or severity of hypertension can be increased when Tolmetin is combined with Flupentixol.]
[M03BX04, tolperisone, Tolperisone may increase the central nervous system depressant (CNS depressant) activities of Flupentixol.]
[N02AX02, tramadol, The risk or severity of serotonin syndrome can be increased when Flupentixol is combined with Tramadol.]
[N06AF04, tranylcypromine, Tranylcypromine may increase the central nervous system depressant (CNS depressant) activities of Flupentixol.]
[N06AX05, trazodone, The risk or severity of QTc prolongation can be increased when Trazodone is combined with Flupentixol.]
[N05CD05, triazolam, Flupentixol may increase the sedative activities of Triazolam.]
[C03AA06, trichlormethiazide, Flupentixol may decrease the antihypertensive activities of Trichlormethiazide.]
[A03AB12, mepenzolate, Flupentixol may increase the central nervous system depressant (CNS depressant) activities of Mepenzolate.]
[N05AB06, trifluoperazine, Trifluoperazine may increase the orthostatic hypotensive, hypotensive, and antihypertensive activities of Flupentixol.]
[N05AD02, trifluperidol, Trifluperidol may increase the central nervous system depressant (CNS depressant) activities of Flupentixol.]
[N05AA05, triflupromazine, Triflupromazine may increase the central nervous system depressant (CNS depressant) activities of Flupentixol.]
[N04AA01, trihexyphenidyl, The therapeutic efficacy of Trihexyphenidyl can be decreased when used in combination with Flupentixol.]
[A03AA05, trimebutine, Flupentixol may increase the central nervous system depressant (CNS depressant) activities of Trimebutine.]
[R06AD01, trimeprazine, Alimemazine may increase the central nervous system depressant (CNS depressant) activities of Flupentixol.]
[N03AC02, trimethadione, Trimethadione may increase the central nervous system depressant (CNS depressant) activities of Flupentixol.]
[C02BA01, trimethaphan, Flupentixol may decrease the antihypertensive activities of Trimethaphan.]
[N06AA06, trimipramine, Trimipramine may increase the orthostatic hypotensive, hypotensive, and antihypertensive activities of Flupentixol.]
[R06AX07, triprolidine, Triprolidine may increase the central nervous system depressant (CNS depressant) activities of Flupentixol.]
[A03BB01, butylscopolamine, Flupentixol may increase the central nervous system depressant (CNS depressant) activities of Butylscopolamine.]
[N06AX24, vilazodone, Vilazodone may increase the central nervous system depressant (CNS depressant) activities of Flupentixol.]
[N06AX02, tryptophan, Tryptophan may increase the central nervous system depressant (CNS depressant) activities of Flupentixol.]
[C09CA09, azilsartan medoxomil, Flupentixol may decrease the antihypertensive activities of Azilsartan medoxomil.]
[M03AA02, tubocurarine, Tubocurarine may increase the central nervous system depressant (CNS depressant) activities of Flupentixol.]
[L01EX04, vandetanib, The risk or severity of QTc prolongation can be increased when Vandetanib is combined with Flupentixol.]
[J05AG05, rilpivirine, The risk or severity of QTc prolongation can be increased when Rilpivirine is combined with Flupentixol.]
[N03AX21, ezogabine, Ezogabine may increase the central nervous system depressant (CNS depressant) activities of Flupentixol.]
[R03AC18, indacaterol, The therapeutic efficacy of Indacaterol can be decreased when used in combination with Flupentixol.]
[C08DA01, verapamil, Verapamil may increase the orthostatic hypotensive, hypotensive, and antihypertensive activities of Flupentixol.]
[N06AX09, viloxazine, Viloxazine may increase the central nervous system depressant (CNS depressant) activities of Flupentixol.]
[L01CA01, vinblastine, The risk or severity of myelosuppression can be increased when Flupentixol is combined with Vinblastine.]
[C04AX07, vincamine, Flupentixol may decrease the antihypertensive activities of Vincamine.]
[L01CA02, vincristine, Vincristine may increase the neurotoxic activities of Flupentixol.]
[L01CA03, vindesine, The risk or severity of myelosuppression can be increased when Flupentixol is combined with Vindesine.]
[B01AA03, warfarin, The risk or severity of adverse effects can be increased when Flupentixol is combined with Warfarin.]
[N01AX15, xenon, The risk or severity of hypertension can be increased when Flupentixol is combined with Xenon.]
[C03BA10, xipamide, Flupentixol may decrease the antihypertensive activities of Xipamide.]
[J05AF01, zidovudine, The risk or severity of myelosuppression can be increased when Flupentixol is combined with Zidovudine.]
[N05AF05, zuclopenthixol, The risk or severity of QTc prolongation can be increased when Zuclopenthixol is combined with Flupentixol.]
[N03AX14, levetiracetam, Levetiracetam may increase the central nervous system depressant (CNS depressant) activities of Flupentixol.]
[L01EC01, vemurafenib, The risk or severity of QTc prolongation can be increased when Vemurafenib is combined with Flupentixol.]
[L01ED01, crizotinib, The risk or severity of QTc prolongation can be increased when Crizotinib is combined with Flupentixol.]
[M05BA06, ibandronic acid, The risk or severity of QTc prolongation can be increased when Ibandronate is combined with Flupentixol.]
[J01MA13, trovafloxacin, The risk or severity of QTc prolongation can be increased when Trovafloxacin is combined with Flupentixol.]
[N05AE04, ziprasidone, The risk or severity of QTc prolongation can be increased when Flupentixol is combined with Ziprasidone.]
[L04AA34, alemtuzumab, The risk or severity of myelosuppression can be increased when Flupentixol is combined with Alemtuzumab.]
[N02BA01, aspirin, The risk or severity of hypertension can be increased when Flupentixol is combined with Acetylsalicylic acid.]
[L01EJ01, ruxolitinib, The risk or severity of myelosuppression can be increased when Flupentixol is combined with Ruxolitinib.]
[G04BD07, tolterodine, Flupentixol may increase the central nervous system depressant (CNS depressant) activities of Tolterodine.]
[C07AB03, atenolol, Atenolol may increase the orthostatic hypotensive activities of Flupentixol.]
[L03AB11, peginterferon alfa-2a, The risk or severity of myelosuppression can be increased when Flupentixol is combined with Peginterferon alfa-2a.]
[L01FA01, rituximab, The risk or severity of myelosuppression can be increased when Flupentixol is combined with Rituximab.]
[J02AC03, voriconazole, The risk or severity of QTc prolongation can be increased when Voriconazole is combined with Flupentixol.]
[M03AC04, atracurium, Atracurium may increase the central nervous system depressant (CNS depressant) activities of Flupentixol.]
[S01FA01, atropine, The risk or severity of QTc prolongation can be increased when Atropine is combined with Flupentixol.]
[L01BC07, azacitidine, The risk or severity of myelosuppression can be increased when Flupentixol is combined with Azacitidine.]
[L01BC05, gemcitabine, The risk or severity of myelosuppression can be increased when Flupentixol is combined with Gemcitabine.]
[G04BE10, avanafil, Flupentixol may increase the hypotensive activities of Avanafil.]
[M03BX01, baclofen, Baclofen may increase the central nervous system depressant (CNS depressant) activities of Flupentixol.]
[L01FX02, gemtuzumab ozogamicin, The risk or severity of myelosuppression can be increased when Flupentixol is combined with Gemtuzumab ozogamicin.]
[A08AA11, lorcaserin, Lorcaserin may increase the central nervous system depressant (CNS depressant) activities of Flupentixol.]
[G04BD12, mirabegron, The risk or severity of urinary retention can be increased when Flupentixol is combined with Mirabegron.]
[L01XG02, carfilzomib, The risk or severity of myelosuppression can be increased when Flupentixol is combined with Carfilzomib.]
[A06AX04, linaclotide, The therapeutic efficacy of Linaclotide can be decreased when used in combination with Flupentixol.]
[L01EA04, bosutinib, The risk or severity of myelosuppression can be increased when Flupentixol is combined with Bosutinib.]
[C01CA18, octopamine, The therapeutic efficacy of Octopamine can be decreased when used in combination with Flupentixol.]
[N05CA04, barbital, Flupentixol may increase the sedative activities of Barbital.]
[J05AE04, nelfinavir, The risk or severity of QTc prolongation can be increased when Nelfinavir is combined with Flupentixol.]
[L01AA09, bendamustine, The risk or severity of myelosuppression can be increased when Flupentixol is combined with Bendamustine.]
[S01GA07, brimonidine, Brimonidine may increase the central nervous system depressant (CNS depressant) activities of Flupentixol.]
[N04BD02, rasagiline, The therapeutic efficacy of Rasagiline can be decreased when used in combination with Flupentixol.]
[C08CA13, lercanidipine, The risk or severity of hypotension can be increased when Flupentixol is combined with Lercanidipine.]
[A03FA09, mosapride, Mosapride may increase the central nervous system depressant (CNS depressant) activities of Flupentixol.]
[N06DA02, donepezil, Donepezil may increase the central nervous system depressant (CNS depressant) activities of Flupentixol.]
[N03AX22, perampanel, Perampanel may increase the central nervous system depressant (CNS depressant) activities of Flupentixol.]
[L04AA29, tofacitinib, The risk or severity of myelosuppression can be increased when Flupentixol is combined with Tofacitinib.]
[N02CC03, zolmitriptan, Zolmitriptan may increase the central nervous system depressant (CNS depressant) activities of Flupentixol.]
[R06AC06, thonzylamine, Flupentixol may increase the central nervous system depressant (CNS depressant) activities of Thonzylamine.]
[G04BD10, darifenacin, Flupentixol may increase the central nervous system depressant (CNS depressant) activities of Darifenacin.]
[N01AA01, ethyl ether, Diethyl ether may increase the central nervous system depressant (CNS depressant) activities of Flupentixol.]
[H01CB05, pasireotide, The risk or severity of QTc prolongation can be increased when Pasireotide is combined with Flupentixol.]
[G04BE03, sildenafil, The risk or severity of hypotension and syncope can be increased when Sildenafil is combined with Flupentixol.]
[L01EA05, ponatinib, The risk or severity of myelosuppression can be increased when Flupentixol is combined with Ponatinib.]
[J04AK05, bedaquiline, The risk or severity of QTc prolongation can be increased when Bedaquiline is combined with Flupentixol.]
[C04AX11, bencyclane, The risk or severity of hypotension can be increased when Flupentixol is combined with Bencyclane.]
[C03AA01, bendroflumethiazide, Flupentixol may decrease the antihypertensive activities of Bendroflumethiazide.]
[L04AX06, pomalidomide, The risk or severity of myelosuppression can be increased when Flupentixol is combined with Pomalidomide.]
[N02BA10, benorilate, The risk or severity of hypertension can be increased when Flupentixol is combined with Benorilate.]
[N05AD07, benperidol, Benperidol may increase the central nervous system depressant (CNS depressant) activities of Flupentixol.]
[J01MA15, gemifloxacin, The risk or severity of QTc prolongation can be increased when Gemifloxacin is combined with Flupentixol.]
[S01AE07, moxifloxacin, The risk or severity of QTc prolongation can be increased when Moxifloxacin is combined with Flupentixol.]
[A06AX06, tegaserod, The risk or severity of serotonin syndrome can be increased when Flupentixol is combined with Tegaserod.]
[R02AD01, benzocaine, Benzocaine may increase the central nervous system depressant (CNS depressant) activities of Flupentixol.]
[A10BX05, pramlintide, The risk or severity of reduced gastrointestinal motility can be increased when Pramlintide is combined with Flupentixol.]
[M01AH01, celecoxib, The risk or severity of hypertension can be increased when Celecoxib is combined with Flupentixol.]
[N02CC02, naratriptan, Naratriptan may increase the central nervous system depressant (CNS depressant) activities of Flupentixol.]
[L04AA18, everolimus, The risk or severity of myelosuppression can be increased when Flupentixol is combined with Everolimus.]
[N04AC01, benztropine, The risk or severity of adverse effects can be increased when Flupentixol is combined with Benzatropine.]
[L01EC02, dabrafenib, The risk or severity of QTc prolongation can be increased when Dabrafenib is combined with Flupentixol.]
[R02AX03, benzydamine, The risk or severity of hypertension can be increased when Flupentixol is combined with Benzydamine.]
[P03AX06, benzyl alcohol, Benzyl alcohol may increase the central nervous system depressant (CNS depressant) activities of Flupentixol.]
[N06AX28, levomilnacipran, The risk or severity of adverse effects can be increased when Flupentixol is combined with Levomilnacipran.]
[C08EA02, bepridil, The risk or severity of QTc prolongation can be increased when Bepridil is combined with Flupentixol.]
[C02KX05, riociguat, Flupentixol may decrease the antihypertensive activities of Riociguat.]
[C02KX04, macitentan, Flupentixol may decrease the antihypertensive activities of Macitentan.]
[L01EL01, ibrutinib, The risk or severity of myelosuppression can be increased when Flupentixol is combined with Ibrutinib.]
[N06AX26, vortioxetine, Vortioxetine may increase the central nervous system depressant (CNS depressant) activities of Flupentixol.]
[N03AF04, eslicarbazepine, Eslicarbazepine may increase the central nervous system depressant (CNS depressant) activities of Flupentixol.]
[N03AG04, vigabatrin, Vigabatrin may increase the central nervous system depressant (CNS depressant) activities of Flupentixol.]
[C01CA27, droxidopa, The therapeutic efficacy of Droxidopa can be decreased when used in combination with Flupentixol.]
[C07AB04, acebutolol, Acebutolol may increase the orthostatic hypotensive activities of Flupentixol.]
[N05CH03, tasimelteon, Flupentixol may increase the sedative activities of Tasimelteon.]
[S01ED02, betaxolol, Betaxolol may increase the orthostatic hypotensive activities of Flupentixol.]
[C02CC01, bethanidine, The therapeutic efficacy of Bethanidine can be decreased when used in combination with Flupentixol.]
[L01ED02, ceritinib, The risk or severity of QTc prolongation can be increased when Ceritinib is combined with Flupentixol.]
[A03BA03, hyoscyamine, Flupentixol may increase the central nervous system depressant (CNS depressant) activities of Hyoscyamine.]
[B01AA07, acenocoumarol, The risk or severity of adverse effects can be increased when Flupentixol is combined with Acenocoumarol.]
[L01XH04, belinostat, The risk or severity of myelosuppression can be increased when Flupentixol is combined with Belinostat.]
[N01AX05, alfaxalone, Alfaxalone may increase the central nervous system depressant (CNS depressant) activities of Flupentixol.]
[R03AC19, olodaterol, The therapeutic efficacy of Olodaterol can be decreased when used in combination with Flupentixol.]
[L03AB13, peginterferon beta-1a, The risk or severity of myelosuppression can be increased when Flupentixol is combined with Peginterferon beta-1a.]
[D11AA01, glycopyrronium, The risk or severity of adverse effects can be increased when Flupentixol is combined with Glycopyrronium.]
[N05CM19, suvorexant, Flupentixol may increase the central nervous system depressant (CNS depressant) activities of Suvorexant.]
[A16AX10, eliglustat, The risk or severity of QTc prolongation can be increased when Eliglustat is combined with Flupentixol.]
[N05AA04, acepromazine, Flupentixol may increase the orthostatic hypotensive, hypotensive, and antihypertensive activities of Acepromazine.]
[A06AB04, phenolphthalein, The therapeutic efficacy of Phenolphthalein can be decreased when used in combination with Flupentixol.]
[L01BC08, decitabine, The risk or severity of myelosuppression can be increased when Flupentixol is combined with Decitabine.]
[N04AA02, biperiden, The therapeutic efficacy of Biperiden can be decreased when used in combination with Flupentixol.]
[A06AG02, bisacodyl, The therapeutic efficacy of Bisacodyl can be decreased when used in combination with Flupentixol.]
[L01FX07, blinatumomab, The risk or severity of myelosuppression can be increased when Flupentixol is combined with Blinatumomab.]
[L01XK01, olaparib, The risk or severity of myelosuppression can be increased when Flupentixol is combined with Olaparib.]
[B01AA01, dicumarol, The risk or severity of adverse effects can be increased when Flupentixol is combined with Dicoumarol.]
[N06AX11, mirtazapine, Flupentixol may increase the serotonergic activities of Mirtazapine.]
[L01EF01, palbociclib, The risk or severity of myelosuppression can be increased when Flupentixol is combined with Palbociclib.]
[L01EX08, lenvatinib, The risk or severity of QTc prolongation can be increased when Lenvatinib is combined with Flupentixol.]
[L01XH03, panobinostat, The risk or severity of QTc prolongation can be increased when Panobinostat is combined with Flupentixol.]
[A03AA09, difemerine, Flupentixol may increase the central nervous system depressant (CNS depressant) activities of Difemerine.]
[B01AA11, tioclomarol, The risk or severity of adverse effects can be increased when Flupentixol is combined with Tioclomarol.]
[C01EB17, ivabradine, The risk or severity of QTc prolongation can be increased when Ivabradine is combined with Flupentixol.]
[A07DA06, eluxadoline, The risk or severity of constipation can be increased when Flupentixol is combined with Eluxadoline.]
[N05AX16, brexpiprazole, Flupentixol may increase the orthostatic hypotensive, hypotensive, and antihypertensive activities of Brexpiprazole.]
[G02CX02, flibanserin, Flibanserin may increase the central nervous system depressant (CNS depressant) activities of Flupentixol.]
[A06AD03, magnesium peroxide, The therapeutic efficacy of Magnesium peroxide can be decreased when used in combination with Flupentixol.]
[N05AX15, cariprazine, Cariprazine may increase the central nervous system depressant (CNS depressant) activities of Flupentixol.]
[M02AA25, aceclofenac, The risk or severity of hypertension can be increased when Flupentixol is combined with Aceclofenac.]
[M01AB11, acemetacin, The risk or severity of hypertension can be increased when Flupentixol is combined with Acemetacin.]
[S01EC01, acetazolamide, Acetazolamide may increase the central nervous system depressant (CNS depressant) activities of Flupentixol.]
[N05AB07, acetophenazine, Acetophenazine may increase the central nervous system depressant (CNS depressant) activities of Flupentixol.]
[L01CX01, trabectedin, The risk or severity of myelosuppression can be increased when Flupentixol is combined with Trabectedin.]
[B01AC27, selexipag, Flupentixol may decrease the antihypertensive activities of Selexipag.]
[G04CA01, alfuzosin, Flupentixol may increase the hypotensive activities of Alfuzosin.]
[N05CA05, aprobarbital, Flupentixol may increase the sedative activities of Aprobarbital.]
[M01AE16, alminoprofen, The risk or severity of hypertension can be increased when Flupentixol is combined with Alminoprofen.]
[N03AX23, brivaracetam, Brivaracetam may increase the central nervous system depressant (CNS depressant) activities of Flupentixol.]
[N05BA08, bromazepam, Flupentixol may increase the sedative activities of Bromazepam.]
[N04BC01, bromocriptine, The therapeutic efficacy of Bromocriptine can be decreased when used in combination with Flupentixol.]
[A03AX08, alverine, Alverine may increase the central nervous system depressant (CNS depressant) activities of Flupentixol.]
[R06AB01, brompheniramine, Dexbrompheniramine may increase the central nervous system depressant (CNS depressant) activities of Flupentixol.]
[N06AA19, amineptin, Amineptine may increase the central nervous system depressant (CNS depressant) activities of Flupentixol.]
[C08CA01, amlodipine, The risk or severity of hypotension can be increased when Flupentixol is combined with Amlodipine.]
[N05AX17, pimavanserin, Flupentixol may increase the neurotoxic activities of Pimavanserin.]
[N06BX11, aniracetam, Aniracetam may increase the central nervous system depressant (CNS depressant) activities of Flupentixol.]
[N01BB01, bupivacaine, Bupivacaine may increase the central nervous system depressant (CNS depressant) activities of Flupentixol.]
[C07AA19, bupranolol, Bupranolol may increase the orthostatic hypotensive activities of Flupentixol.]
[N07BC01, buprenorphine, Flupentixol may increase the central nervous system depressant (CNS depressant) activities of Buprenorphine.]
[L02AE01, buserelin, The risk or severity of QTc prolongation can be increased when Buserelin is combined with Flupentixol.]
[N05BE01, buspirone, Buspirone may increase the central nervous system depressant (CNS depressant) activities of Flupentixol.]
[L01AB01, busulfan, The risk or severity of myelosuppression can be increased when Flupentixol is combined with Busulfan.]
[L01XX27, arsenic trioxide, The risk or severity of QTc prolongation can be increased when Arsenic trioxide is combined with Flupentixol.]
[P01BE02, artemether, The risk or severity of QTc prolongation can be increased when Artemether is combined with Flupentixol.]
[N02AF01, butorphanol, Butorphanol may increase the central nervous system depressant (CNS depressant) activities of Flupentixol.]
[J01MA09, sparfloxacin, The risk or severity of QTc prolongation can be increased when Sparfloxacin is combined with Flupentixol.]
[R06AX09, azatadine, The risk or severity of QTc prolongation can be increased when Azatadine is combined with Flupentixol.]
[S01GX07, azelastine, Flupentixol may increase the central nervous system depressant (CNS depressant) activities of Azelastine.]
[S01AA26, azithromycin, The risk or severity of QTc prolongation can be increased when Azithromycin is combined with Flupentixol.]
[A06AX07, plecanatide, The therapeutic efficacy of Plecanatide can be decreased when used in combination with Flupentixol.]
[L01EF02, ribociclib, The risk or severity of QTc prolongation can be increased when Ribociclib is combined with Flupentixol.]
[A07EC04, balsalazide, The risk or severity of hypertension can be increased when Flupentixol is combined with Balsalazide.]
[R03CC12, bambuterol, The therapeutic efficacy of Bambuterol can be decreased when used in combination with Flupentixol.]
[N07XX16, deutetrabenazine, The risk or severity of QTc prolongation can be increased when Deutetrabenazine is combined with Flupentixol.]
[N02BF02, pregabalin, The therapeutic efficacy of Flupentixol can be increased when used in combination with Pregabalin.]
[N03AX30, beclamide, Beclamide may increase the central nervous system depressant (CNS depressant) activities of Flupentixol.]
[C09AA07, benazepril, Flupentixol may decrease the antihypertensive activities of Benazepril.]
[S01HA02, benoxinate, Oxybuprocaine may increase the central nervous system depressant (CNS depressant) activities of Flupentixol.]
[J01XX08, linezolid, The risk or severity of serotonin syndrome can be increased when Linezolid is combined with Flupentixol.]
[N04BD03, safinamide, The therapeutic efficacy of Safinamide can be decreased when used in combination with Flupentixol.]
[J01MA23, delafloxacin, The risk or severity of QTc prolongation can be increased when Delafloxacin is combined with Flupentixol.]
[L01BC06, capecitabine, The risk or severity of myelosuppression can be increased when Flupentixol is combined with Capecitabine.]
[L01XH01, vorinostat, The risk or severity of myelosuppression can be increased when Flupentixol is combined with Vorinostat.]
[A02BX12, bismuth subnitrate, Flupentixol may increase the neurotoxic activities of Bismuth subnitrate.]
[C07AB07, bisoprolol, Bisoprolol may increase the orthostatic hypotensive activities of Flupentixol.]
[R03AC17, bitolterol, The therapeutic efficacy of Bitolterol can be decreased when used in combination with Flupentixol.]
[J05AG03, efavirenz, The risk or severity of QTc prolongation can be increased when Efavirenz is combined with Flupentixol.]
[C07AA17, bopindolol, Bopindolol may increase the orthostatic hypotensive activities of Flupentixol.]
[N04AA11, bornaprine, The therapeutic efficacy of Bornaprine can be decreased when used in combination with Flupentixol.]
[L01BA03, raltitrexed, The risk or severity of myelosuppression can be increased when Flupentixol is combined with Raltitrexed.]
[N05AD06, bromperidol, Bromperidol may increase the central nervous system depressant (CNS depressant) activities of Flupentixol.]
[N05CD09, brotizolam, Flupentixol may increase the sedative activities of Brotizolam.]
[N04BX03, budipine, The therapeutic efficacy of Budipine can be decreased when used in combination with Flupentixol.]
[C04AX20, buflomedil, The risk or severity of hypertension can be increased when Flupentixol is combined with Buflomedil.]
[M01AB07, bumadizone, The risk or severity of hypertension can be increased when Flupentixol is combined with Bumadizone.]
[N05CA03, butobarbital, Flupentixol may increase the sedative activities of Butobarbital.]
[N06AA15, butriptyline, The risk or severity of QTc prolongation can be increased when Butriptyline is combined with Flupentixol.]
[C01AA02, acetyldigoxins, The risk or severity of QTc prolongation can be increased when Acetyldigoxin is combined with Flupentixol.]
[N05CA08, butylvinal, Flupentixol may increase the sedative activities of Vinylbital.]
[R06AX18, acrivastine, The risk or severity of QTc prolongation can be increased when Acrivastine is combined with Flupentixol.]
[C09AA01, captopril, Flupentixol may decrease the antihypertensive activities of Captopril.]
[V04CD06, macimorelin, The therapeutic efficacy of Macimorelin can be decreased when used in combination with Flupentixol.]
[N03AF01, carbamazepine, The risk or severity of myelosuppression can be increased when Flupentixol is combined with Carbamazepine.]
[A06AC08, calcium polycarbophil, The therapeutic efficacy of Calcium polycarbophil can be decreased when used in combination with Flupentixol.]
[A03AA03, camylofine, Flupentixol may increase the central nervous system depressant (CNS depressant) activities of Camylofin.]
[R06AA08, carbinoxamine, The risk or severity of QTc prolongation can be increased when Carbinoxamine is combined with Flupentixol.]
[L03AB06, interferon alfa-n1, The risk or severity of myelosuppression can be increased when Flupentixol is combined with Interferon alfa-n1.]
[C07AG02, carvedilol, Flupentixol may increase the orthostatic hypotensive, hypotensive, and antihypertensive activities of Carvedilol.]
[B02BX09, fostamatinib, The risk or severity of hypotension and syncope can be increased when Fostamatinib is combined with Flupentixol.]
[N03AX24, cannabidiol, The risk or severity of adverse effects can be increased when Cannabidiol is combined with Flupentixol.]
[L01EC03, encorafenib, The risk or severity of QTc prolongation can be increased when Encorafenib is combined with Flupentixol.]
[C07AB08, celiprolol, The therapeutic efficacy of Celiprolol can be decreased when used in combination with Flupentixol.]
[L01XX62, ivosidenib, The risk or severity of QTc prolongation can be increased when Ivosidenib is combined with Flupentixol.]
[N03AX17, stiripentol, Stiripentol may increase the central nervous system depressant (CNS depressant) activities of Flupentixol.]
[S01GX12, cetirizine, Cetirizine may increase the central nervous system depressant (CNS depressant) activities of Flupentixol.]
[N05CM04, carbromal, Flupentixol may increase the sedative activities of Carbromal.]
[N01BA04, chloroprocaine, Chloroprocaine may increase the central nervous system depressant (CNS depressant) activities of Flupentixol.]
[R06AA06, chlorphenoxamine, Flupentixol may increase the central nervous system depressant (CNS depressant) activities of Chlorphenoxamine.]
[M01AC05, lornoxicam, The risk or severity of hypertension can be increased when Flupentixol is combined with Lornoxicam.]
[N07XX15, inotersen, The risk or severity of QTc prolongation can be increased when Inotersen is combined with Flupentixol.]
[M03BA02, carisoprodol, The risk or severity of adverse effects can be increased when Carisoprodol is combined with Flupentixol.]
[R03BB08, revefenacin, Flupentixol may increase the central nervous system depressant (CNS depressant) activities of Revefenacin.]
[L01AD01, carmustine, The risk or severity of myelosuppression can be increased when Flupentixol is combined with Carmustine.]
[L01EX13, gilteritinib, The therapeutic efficacy of Flupentixol can be decreased when used in combination with Gilteritinib.]
[L01XJ03, glasdegib, The risk or severity of QTc prolongation can be increased when Glasdegib is combined with Flupentixol.]
[N07XX05, amifampridine, The risk or severity of QTc prolongation can be increased when Amifampridine is combined with Flupentixol.]
[A06AX05, prucalopride, The therapeutic efficacy of Prucalopride can be decreased when used in combination with Flupentixol.]
[C01BG07, cifenline, The risk or severity of QTc prolongation can be increased when Cibenzoline is combined with Flupentixol.]
[C09AA08, cilazapril, Flupentixol may decrease the antihypertensive activities of Cilazapril.]
[B01AC23, cilostazol, The risk or severity of QTc prolongation can be increased when Cilostazol is combined with Flupentixol.]
[A03FA08, cinitapride, Cinitapride may increase the central nervous system depressant (CNS depressant) activities of Flupentixol.]
[P02BX04, triclabendazole, The risk or severity of QTc prolongation can be increased when Triclabendazole is combined with Flupentixol.]
[N06AX27, esketamine, The risk or severity of hypertension can be increased when Esketamine is combined with Flupentixol.]
[L04AA42, siponimod, The risk or severity of hypertension can be increased when Flupentixol is combined with Siponimod.]
[J01FA09, clarithromycin, The risk or severity of QTc prolongation can be increased when Clarithromycin is combined with Flupentixol.]
[N06BA14, solriamfetol, The risk or severity of hypertension can be increased when Solriamfetol is combined with Flupentixol.]
[N06AX29, brexanolone, Brexanolone may increase the central nervous system depressant (CNS depressant) activities of Flupentixol.]
[N05BA09, clobazam, Clobazam may increase the central nervous system depressant (CNS depressant) activities of Flupentixol.]
[A06AB05, castor oil, The therapeutic efficacy of Castor oil can be decreased when used in combination with Flupentixol.]
[N05BA22, cloxazolam, Cloxazolam may increase the central nervous system depressant (CNS depressant) activities of Flupentixol.]
[C09CA06, candesartan, Flupentixol may decrease the antihypertensive activities of Candesartan.]
[N05AA06, cyamemazine, Cyamemazine may increase the central nervous system depressant (CNS depressant) activities of Flupentixol.]
[C03BX03, cicletanine, The risk or severity of QTc prolongation can be increased when Cicletanine is combined with Flupentixol.]
[M03BX08, cyclobenzaprine, The risk or severity of CNS depression can be increased when Cyclobenzaprine is combined with Flupentixol.]
[L01EX14, entrectinib, The risk or severity of QTc prolongation can be increased when Flupentixol is combined with Entrectinib.]
[N07XX11, pitolisant, The risk or severity of QTc prolongation can be increased when Pitolisant is combined with Flupentixol.]
[J01XX12, lefamulin, Lefamulin may increase the QTc-prolonging activities of Flupentixol.]
[N04CX01, istradefylline, The therapeutic efficacy of Istradefylline can be decreased when used in combination with Flupentixol.]
[C03AA09, cyclothiazide, Flupentixol may decrease the antihypertensive activities of Cyclothiazide.]
[G04BE04, yohimbine, Yohimbine may increase the central nervous system depressant (CNS depressant) activities of Flupentixol.]
[A06AB03, danthron, The therapeutic efficacy of Dantron can be decreased when used in combination with Flupentixol.]
[L01FD03, ado-trastuzumab emtansine, The risk or severity of myelosuppression can be increased when Flupentixol is combined with Trastuzumab emtansine.]
[N02CC08, lasmiditan, The risk or severity of serotonin syndrome can be increased when Lasmiditan is combined with Flupentixol.]
[R06AB06, dexbrompheniramine, Dexbrompheniramine may increase the central nervous system depressant (CNS depressant) activities of Flupentixol.]
[R06AB02, dexchlorpheniramine, The risk or severity of QTc prolongation can be increased when Dexchlorpheniramine is combined with Flupentixol.]
[N02AX03, dezocine, Dezocine may increase the central nervous system depressant (CNS depressant) activities of Flupentixol.]
[N05CM21, lemborexant, Flupentixol may increase the sedative activities of Lemborexant.]
[N05AD10, lumateperone, Lumateperone may increase the central nervous system depressant (CNS depressant) activities of Flupentixol.]
[S01AE06, gatifloxacin, The risk or severity of QTc prolongation can be increased when Gatifloxacin is combined with Flupentixol.]
[N02CC07, frovatriptan, Frovatriptan may increase the central nervous system depressant (CNS depressant) activities of Flupentixol.]
[G04CB02, dutasteride, The risk or severity of hypertension can be increased when Flupentixol is combined with Dutasteride.]
[N05CC04, dichloralphenazone, Flupentixol may increase the sedative activities of Dichloralphenazone.]
[A07DA04, difenoxin, Difenoxin may increase the central nervous system depressant (CNS depressant) activities of Flupentixol.]
[N02AA08, dihydrocodeine, Dihydrocodeine may increase the central nervous system depressant (CNS depressant) activities of Flupentixol.]
[N02CC06, eletriptan, Eletriptan may increase the central nervous system depressant (CNS depressant) activities of Flupentixol.]
[M01AH02, rofecoxib, The risk or severity of hypertension can be increased when Rofecoxib is combined with Flupentixol.]
[L01XF03, bexarotene, The risk or severity of myelosuppression can be increased when Flupentixol is combined with Bexarotene.]
[C08CA16, clevidipine, The risk or severity of hypotension can be increased when Flupentixol is combined with Clevidipine.]
[C01BD07, dronedarone, Flupentixol may increase the QTc-prolonging activities of Dronedarone.]
[N03AG02, dipropylacetamide, Valpromide may increase the central nervous system depressant (CNS depressant) activities of Flupentixol.]
[L01AA02, chlorambucil, The risk or severity of myelosuppression can be increased when Flupentixol is combined with Chlorambucil.]
[S03AA08, chloramphenicol, The risk or severity of myelosuppression can be increased when Flupentixol is combined with Chloramphenicol.]
[R06AE04, chlorcyclizine, The risk or severity of QTc prolongation can be increased when Chlorcyclizine is combined with Flupentixol.]
[N05BA02, chlordiazepoxide, Flupentixol may increase the sedative activities of Chlordiazepoxide.]
[C02AA06, methoserpidine, Flupentixol may decrease the antihypertensive activities of Methoserpidine.]
[A03AA08, dihexyverine, Flupentixol may increase the central nervous system depressant (CNS depressant) activities of Dihexyverine.]
[N04BX04, opicapone, The therapeutic efficacy of Opicapone can be decreased when used in combination with Flupentixol.]
[C01CA14, dopexamine, The therapeutic efficacy of Dopexamine can be decreased when used in combination with Flupentixol.]
[G04BD09, trospium, Flupentixol may increase the central nervous system depressant (CNS depressant) activities of Trospium.]
[M01AC04, droxicam, The risk or severity of hypertension can be increased when Flupentixol is combined with Droxicam.]
[L01EX22, selpercatinib, The risk or severity of hypertension can be increased when Flupentixol is combined with Selpercatinib.]
[M02AA27, dexketoprofen, The risk or severity of hypertension can be increased when Flupentixol is combined with Dexketoprofen.]
[N05CM02, chlormethiazole, Flupentixol may increase the sedative activities of Clomethiazole.]
[M03BB02, chlormezanone, Chlormezanone may increase the central nervous system depressant (CNS depressant) activities of Flupentixol.]
[R02AD04, dyclonine, Dyclonine may increase the central nervous system depressant (CNS depressant) activities of Flupentixol.]
[C08CA17, levamlodipine, The risk or severity of hypotension can be increased when Flupentixol is combined with Levamlodipine.]
[R06AX22, ebastine, The risk or severity of QTc prolongation can be increased when Ebastine is combined with Flupentixol.]
[J05AX29, fostemsavir, The risk or severity of QTc prolongation can be increased when Fostemsavir is combined with Flupentixol.]
[N05CD14, remimazolam, Flupentixol may increase the sedative activities of Remimazolam.]
[N02AX07, oliceridine, The risk or severity of hypotension, sedation, death, somnolence, and respiratory depression can be increased when Flupentixol is combined with Oliceridine.]
[P01BA01, chloroquine, The risk or severity of QTc prolongation can be increased when Chloroquine is combined with Flupentixol.]
[C03AA04, chlorothiazide, Flupentixol may decrease the antihypertensive activities of Chlorothiazide.]
[R06AB04, chlorpheniramine, The risk or severity of QTc prolongation can be increased when Chlorpheniramine is combined with Flupentixol.]
[N05AA01, chlorpromazine, The risk or severity of QTc prolongation can be increased when Chlorpromazine is combined with Flupentixol.]
[N05AF03, chlorprothixene, Flupentixol may increase the central nervous system depressant (CNS depressant) activities of Chlorprothixene.]
[C03BA04, chlorthalidone, Flupentixol may decrease the antihypertensive activities of Chlorthalidone.]
[M03BB03, chlorzoxazone, Chlorzoxazone may increase the central nervous system depressant (CNS depressant) activities of Flupentixol.]
[N05BX03, etifoxine, Etifoxine may increase the central nervous system depressant (CNS depressant) activities of Flupentixol.]
[N02BA07, ethenzamide, The risk or severity of hypertension can be increased when Flupentixol is combined with Ethenzamide.]
[N06BX18, vinpocetine, Vinpocetine may increase the central nervous system depressant (CNS depressant) activities of Flupentixol.]
[N05BA18, ethyl loflazepate, Ethyl loflazepate may increase the central nervous system depressant (CNS depressant) activities of Flupentixol.]
[M01AB08, etodolac, The risk or severity of hypertension can be increased when Etodolac is combined with Flupentixol.]
[M02AA06, etofenamate, The risk or severity of hypertension can be increased when Flupentixol is combined with Etofenamate.]
[B06AC06, berotralstat, The risk or severity of QTc prolongation can be increased when Berotralstat is combined with Flupentixol.]
[L01BB05, fludarabine, The risk or severity of myelosuppression can be increased when Flupentixol is combined with Fludarabine.]
[L02BX04, relugolix, The risk or severity of QTc prolongation can be increased when Relugolix is combined with Flupentixol.]
[L01FX21, naxitamab, The risk or severity of hypertension can be increased when Flupentixol is combined with Naxitamab.]
[M03BA05, febarbamate, Febarbamate may increase the central nervous system depressant (CNS depressant) activities of Flupentixol.]
[N03AX10, felbamate, Felbamate may increase the central nervous system depressant (CNS depressant) activities of Flupentixol.]
[M01AE05, fenbufen, The risk or severity of hypertension can be increased when Flupentixol is combined with Fenbufen.]
[C01CA19, fenoldopam, The therapeutic efficacy of Fenoldopam can be decreased when used in combination with Flupentixol.]
[N06BA08, fenozolone, The risk or severity of hypertension can be increased when Flupentixol is combined with Fenozolone.]
[G04CB01, finasteride, The risk or severity of hypertension can be increased when Flupentixol is combined with Finasteride.]
[J01MB07, flumequine, The risk or severity of QTc prolongation can be increased when Flumequine is combined with Flupentixol.]
[R03CC15, formoterol, The therapeutic efficacy of Formoterol can be decreased when used in combination with Flupentixol.]
[L04AA50, ponesimod, The risk or severity of bradycardia can be increased when Ponesimod is combined with Flupentixol.]
[N01AB05, trichloroethylene, Trichloroethylene may increase the central nervous system depressant (CNS depressant) activities of Flupentixol.]
[L03AB10, peginterferon alfa-2b, The risk or severity of myelosuppression can be increased when Flupentixol is combined with Peginterferon alfa-2b.]
[H04AA02, dasiglucagon, Flupentixol may decrease the antihypertensive activities of Dasiglucagon.]
[N02BF01, gabapentin, Gabapentin may increase the central nervous system depressant (CNS depressant) activities of Flupentixol.]
[N07CA02, cinnarizine, The risk or severity of QTc prolongation can be increased when Cinnarizine is combined with Flupentixol.]
[J01MB06, cinoxacin, The risk or severity of QTc prolongation can be increased when Cinoxacin is combined with Flupentixol.]
[S03AA07, ciprofloxacin, The risk or severity of QTc prolongation can be increased when Ciprofloxacin is combined with Flupentixol.]
[L01XA01, cisplatin, The risk or severity of myelosuppression can be increased when Flupentixol is combined with Cisplatin.]
[N06AB04, citalopram, The risk or severity of QTc prolongation can be increased when Citalopram is combined with Flupentixol.]
[P01CA03, fexinidazole, The risk or severity of adverse effects can be increased when Flupentixol is combined with Fexinidazole.]
[L01EB10, mobocertinib, The risk or severity of QTc prolongation can be increased when Flupentixol is combined with Mobocertinib.]
[R06AA04, clemastine, The risk or severity of QTc prolongation can be increased when Clemastine is combined with Flupentixol.]
[R03CC13, clenbuterol, The therapeutic efficacy of Clenbuterol can be decreased when used in combination with Flupentixol.]
[J01FF01, clindamycin, Flupentixol may increase the neurotoxic activities of Clindamycin.]
[N06AX25, St. John's wort extract, St. John's Wort may increase the central nervous system depressant (CNS depressant) activities of Flupentixol.]
[L03AB15, ropeginterferon alfa-2b, The risk or severity of neuropsychiatric effects can be increased when Ropeginterferon alfa-2b is combined with Flupentixol.]
[J04BA01, clofazimine, The risk or severity of QTc prolongation can be increased when Clofazimine is combined with Flupentixol.]
[N01BB10, levobupivacaine, Levobupivacaine may increase the central nervous system depressant (CNS depressant) activities of Flupentixol.]
[L01EJ03, pacritinib, The risk or severity of QTc prolongation can be increased when Pacritinib is combined with Flupentixol.]
[N06AA04, clomipramine, The risk or severity of QTc prolongation can be increased when Clomipramine is combined with Flupentixol.]
[N03AE01, clonazepam, Clonazepam may increase the central nervous system depressant (CNS depressant) activities of Flupentixol.]
[S01EA04, clonidine, The risk or severity of sedation can be increased when Clonidine is combined with Flupentixol.]
[N05AH06, clothiapine, Clothiapine may increase the central nervous system depressant (CNS depressant) activities of Flupentixol.]
[N05BA21, clotiazepam, Clotiazepam may increase the central nervous system depressant (CNS depressant) activities of Flupentixol.]
[A04AA01, ondansetron, The risk or severity of QTc prolongation can be increased when Ondansetron is combined with Flupentixol.]
[A04AA02, granisetron, The risk or severity of QTc prolongation can be increased when Granisetron is combined with Flupentixol.]
[N05AH02, clozapine, The risk or severity of QTc prolongation can be increased when Clozapine is combined with Flupentixol.]
[N05BA13, halazepam, Halazepam may increase the central nervous system depressant (CNS depressant) activities of Flupentixol.]
[S02DA02, cocaine, The risk or severity of QTc prolongation can be increased when Flupentixol is combined with Cocaine.]
[C02KB01, metyrosine, Flupentixol may increase the sedative activities of Metyrosine.]
[M01AX13, proquazone, The risk or severity of hypertension can be increased when Flupentixol is combined with Proquazone.]
[R05DA04, codeine, Codeine may increase the central nervous system depressant (CNS depressant) activities of Flupentixol.]
[M03AC05, hexafluorenium, Hexafluronium may increase the central nervous system depressant (CNS depressant) activities of Flupentixol.]
[A03AB10, hexocyclium, Flupentixol may increase the central nervous system depressant (CNS depressant) activities of Hexocyclium.]
[A03BB06, homatropine methylbromide, Flupentixol may increase the central nervous system depressant (CNS depressant) activities of Homatropine methylbromide.]
[N01AB07, desflurane, Desflurane may increase the central nervous system depressant (CNS depressant) activities of Flupentixol.]
[A04AA03, tropisetron, Tropisetron may increase the central nervous system depressant (CNS depressant) activities of Flupentixol.]
[C04AX28, ifenprodil, The therapeutic efficacy of Ifenprodil can be decreased when used in combination with Flupentixol.]
[N02BA16, imidazole-2-hydroxybenzoate, The risk or severity of hypertension can be increased when Flupentixol is combined with Imidazole salicylate.]
[L01BB07, nelarabine, The risk or severity of myelosuppression can be increased when Flupentixol is combined with Nelarabine.]
[J01FA15, telithromycin, The risk or severity of QTc prolongation can be increased when Telithromycin is combined with Flupentixol.]
[B01AC10, indobufen, The risk or severity of hypertension can be increased when Flupentixol is combined with Indobufen.]
[R06AX27, desloratadine, The risk or severity of QTc prolongation can be increased when Desloratadine is combined with Flupentixol.]
[M01AH03, valdecoxib, The risk or severity of hypertension can be increased when Valdecoxib is combined with Flupentixol.]
[A03AX10, isometheptene, The therapeutic efficacy of Isometheptene can be decreased when used in combination with Flupentixol.]
[N02CC05, almotriptan, Almotriptan may increase the central nervous system depressant (CNS depressant) activities of Flupentixol.]
[M01AH04, parecoxib, The risk or severity of hypertension can be increased when Flupentixol is combined with Parecoxib.]
[J02AC02, itraconazole, The risk or severity of QTc prolongation can be increased when Itraconazole is combined with Flupentixol.]
[S01GX06, emedastine, The risk or severity of QTc prolongation can be increased when Emedastine is combined with Flupentixol.]
[N05BA10, ketazolam, Ketazolam may increase the central nervous system depressant (CNS depressant) activities of Flupentixol.]
[M01AA06, kebuzone, The risk or severity of hypertension can be increased when Flupentixol is combined with Kebuzone.]
[L01EA01, imatinib, The risk or severity of QTc prolongation can be increased when Imatinib is combined with Flupentixol.]
[J02AC04, posaconazole, The risk or severity of QTc prolongation can be increased when Posaconazole is combined with Flupentixol.]
[C08CA09, lacidipine, The risk or severity of hypotension can be increased when Flupentixol is combined with Lacidipine.]
[A06AD12, lactitol, The therapeutic efficacy of Lactitol can be decreased when used in combination with Flupentixol.]
[N03AX09, lamotrigine, Lamotrigine may increase the central nervous system depressant (CNS depressant) activities of Flupentixol.]
[S01GX02, levocabastine, Levocabastine may increase the central nervous system depressant (CNS depressant) activities of Flupentixol.]
[N07BC04, lofexidine, The risk or severity of QTc prolongation can be increased when Lofexidine is combined with Flupentixol.]
[S01AE04, lomefloxacin, The risk or severity of QTc prolongation can be increased when Lomefloxacin is combined with Flupentixol.]
[M01AB09, lonazolac, The risk or severity of hypertension can be increased when Flupentixol is combined with Lonazolac.]
[N05CD06, lormetazepam, Flupentixol may increase the sedative activities of Lormetazepam.]
[M02AA31, loxoprofen, The risk or severity of hypertension can be increased when Flupentixol is combined with Loxoprofen.]
[C09AA03, lisinopril, Flupentixol may decrease the antihypertensive activities of Lisinopril.]
[A06AD01, magnesium carbonate, The therapeutic efficacy of Magnesium carbonate can be decreased when used in combination with Flupentixol.]
[C08CA11, manidipine, The risk or severity of hypotension can be increased when Flupentixol is combined with Manidipine.]
[A03AA04, mebeverine, Flupentixol may increase the central nervous system depressant (CNS depressant) activities of Mebeverine.]
[N06AX13, medifoxamine, Medifoxamine may increase the central nervous system depressant (CNS depressant) activities of Flupentixol.]
[A08AA09, mefenorex, The risk or severity of hypertension can be increased when Flupentixol is combined with Mefenorex.]
[C07AA14, mepindolol, Mepindolol may increase the orthostatic hypotensive activities of Flupentixol.]
[R06AD07, mequitazine, Flupentixol may increase the arrhythmogenic activities of Mequitazine.]
[C01EB10, adenosine, The risk or severity of QTc prolongation can be increased when Adenosine is combined with Flupentixol.]
[N04AA03, methixene, The therapeutic efficacy of Metixene can be decreased when used in combination with Flupentixol.]
[C04AX01, cyclandelate, The risk or severity of hypotension can be increased when Flupentixol is combined with Cyclandelate.]
[R03CB02, methoxyphenamine, The therapeutic efficacy of Flupentixol can be decreased when used in combination with Methoxyphenamine.]
[R06AE03, cyclizine, Cyclizine may increase the central nervous system depressant (CNS depressant) activities of Flupentixol.]
[N05CA10, cyclobarbital, Flupentixol may increase the sedative activities of Cyclobarbital.]
[C03DA04, eplerenone, Flupentixol may decrease the antihypertensive activities of Eplerenone.]
[N05AD03, metylperon, The risk or severity of QTc prolongation can be increased when Melperone is combined with Flupentixol.]
[C03AA07, cyclopenthiazide, Flupentixol may decrease the antihypertensive activities of Cyclopenthiazide.]
[L01AA01, cyclophosphamide, The risk or severity of myelosuppression can be increased when Flupentixol is combined with Cyclophosphamide.]
[N06AX07, minaprine, Minaprine may increase the central nervous system depressant (CNS depressant) activities of Flupentixol.]
[J04AB01, cycloserine, Cycloserine may increase the neurotoxic activities of Flupentixol.]
[S01XA18, cyclosporine, The risk or severity of hypertension can be increased when Cyclosporine is combined with Flupentixol.]
[N06AG02, moclobemide, Moclobemide may increase the central nervous system depressant (CNS depressant) activities of Flupentixol.]
[R06AX02, cyproheptadine, Cyproheptadine may increase the central nervous system depressant (CNS depressant) activities of Flupentixol.]
[C09AA13, moexipril, The risk or severity of QTc prolongation can be increased when Moexipril is combined with Flupentixol.]
[M02AA02, mofebutazone, The risk or severity of hypertension can be increased when Flupentixol is combined with Mofebutazone.]
[M01AX22, morniflumate, The risk or severity of hypertension can be increased when Flupentixol is combined with Morniflumate.]
[C02AC05, moxonidine, The therapeutic efficacy of Moxonidine can be decreased when used in combination with Flupentixol.]
[L01BC01, cytarabine, The risk or severity of myelosuppression can be increased when Flupentixol is combined with Cytarabine.]
[G04BE09, vardenafil, The risk or severity of hypotension and syncope can be increased when Vardenafil is combined with Flupentixol.]
[M01AH05, etoricoxib, The risk or severity of hypertension can be increased when Flupentixol is combined with Etoricoxib.]
[L01AX04, dacarbazine, The risk or severity of myelosuppression can be increased when Flupentixol is combined with Dacarbazine.]
[L01DA01, dactinomycin, The risk or severity of myelosuppression can be increased when Flupentixol is combined with Dactinomycin.]
[M03CA01, dantrolene, Dantrolene may increase the central nervous system depressant (CNS depressant) activities of Flupentixol.]
[L01DB02, daunorubicin, The risk or severity of myelosuppression can be increased when Flupentixol is combined with Daunorubicin.]
[N06BX04, deanol, Deanol may increase the central nervous system depressant (CNS depressant) activities of Flupentixol.]
[C02CC04, debrisoquin, Flupentixol may decrease the antihypertensive activities of Debrisoquine.]
[A04AD11, nabilone, Nabilone may increase the central nervous system depressant (CNS depressant) activities of Flupentixol.]
[M01AX01, nabumetone, The risk or severity of hypertension can be increased when Nabumetone is combined with Flupentixol.]
[N05BA16, nordazepam, Nordazepam may increase the central nervous system depressant (CNS depressant) activities of Flupentixol.]
[C07AB12, nebivolol, The therapeutic efficacy of Nebivolol can be decreased when used in combination with Flupentixol.]
[N06AX06, nefazodone, Flupentixol may increase the orthostatic hypotensive, hypotensive, and antihypertensive activities of Nefazodone.]
[N05CM16, niaprazine, Flupentixol may increase the sedative activities of Niaprazine.]
[C01DX16, nicorandil, Flupentixol may decrease the antihypertensive activities of Nicorandil.]
[N03AG06, tiagabine, Tiagabine may increase the central nervous system depressant (CNS depressant) activities of Flupentixol.]
[C01CA23, theodrenaline, Flupentixol may decrease the hypertensive activities of Theodrenaline.]
[M03AC11, cisatracurium, Cisatracurium may increase the central nervous system depressant (CNS depressant) activities of Flupentixol.]
[C01CA05, norfenefrine, The therapeutic efficacy of Norfenefrine can be decreased when used in combination with Flupentixol.]
[R05DA06, normethadone, Normethadone may increase the central nervous system depressant (CNS depressant) activities of Flupentixol.]
[N06AB10, escitalopram, The risk or severity of QTc prolongation can be increased when Escitalopram is combined with Flupentixol.]
[G04BD08, solifenacin, Flupentixol may increase the central nervous system depressant (CNS depressant) activities of Solifenacin.]
[A07EC03, olsalazine, The risk or severity of hypertension can be increased when Flupentixol is combined with Olsalazine.]
[N06AA01, desipramine, Flupentixol may increase the central nervous system depressant (CNS depressant) activities of Desipramine.]
[H01BA02, desmopressin, The risk or severity of hypertension can be increased when Desmopressin is combined with Flupentixol.]
[C09XA02, aliskiren, Flupentixol may decrease the antihypertensive activities of Aliskiren.]
[L01XA03, oxaliplatin, The risk or severity of QTc prolongation can be increased when Oxaliplatin is combined with Flupentixol.]
[M01AE12, oxaprozin, The risk or severity of hypertension can be increased when Flupentixol is combined with Oxaprozin.]
[N03AF02, oxcarbazepine, Oxcarbazepine may increase the central nervous system depressant (CNS depressant) activities of Flupentixol.]
[N06BX07, oxiracetam, Oxiracetam may increase the central nervous system depressant (CNS depressant) activities of Flupentixol.]
[N04AA08, dexetimide, The therapeutic efficacy of Dexetimide can be decreased when used in combination with Flupentixol.]
[G04BD04, oxybutynin, Flupentixol may increase the central nervous system depressant (CNS depressant) activities of Oxybutynin.]
[A08AA04, dexfenfluramine, The risk or severity of serotonin syndrome can be increased when Flupentixol is combined with Dexfenfluramine.]
[A03AA01, oxyphencyclimine, Flupentixol may increase the central nervous system depressant (CNS depressant) activities of Oxyphencyclimine.]
[N06BA02, dextroamphetamine, The therapeutic efficacy of Flupentixol can be decreased when used in combination with Amphetamine.]
[R05DA09, dextromethorphan, Dextromethorphan may increase the central nervous system depressant (CNS depressant) activities of Flupentixol.]
[N03AC01, paramethadione, Paramethadione may increase the central nervous system depressant (CNS depressant) activities of Flupentixol.]
[N02AC01, dextromoramide, Dextromoramide may increase the central nervous system depressant (CNS depressant) activities of Flupentixol.]
[N06AB05, paroxetine, The risk or severity of adverse effects can be increased when Flupentixol is combined with Paroxetine.]
[N07BC06, heroin, Diamorphine may increase the central nervous system depressant (CNS depressant) activities of Flupentixol.]
[N05BA01, diazepam, Flupentixol may increase the sedative activities of Diazepam.]
[N03AX07, phenacemide, Phenacemide may increase the central nervous system depressant (CNS depressant) activities of Flupentixol.]
[V03AH01, diazoxide, Flupentixol may decrease the antihypertensive activities of Diazoxide.]
[N03AD02, phensuximide, Phensuximide may increase the central nervous system depressant (CNS depressant) activities of Flupentixol.]
[N06AA08, dibenzepin, Dibenzepin may increase the central nervous system depressant (CNS depressant) activities of Flupentixol.]
[S02DA04, dibucaine, Cinchocaine may increase the central nervous system depressant (CNS depressant) activities of Flupentixol.]
[S01BC03, diclofenac, The risk or severity of hypertension can be increased when Diclofenac is combined with Flupentixol.]
[J05AD01, foscarnet, The risk or severity of QTc prolongation can be increased when Foscarnet is combined with Flupentixol.]
[A03AA07, dicyclomine, Flupentixol may increase the central nervous system depressant (CNS depressant) activities of Dicyclomine.]
[J05AF02, didanosine, Flupentixol may increase the neurotoxic activities of Didanosine.]
[C02DG01, pinacidil, Flupentixol may decrease the antihypertensive activities of Pinacidil.]
[A03AX04, pinaverium, The risk or severity of hypotension can be increased when Flupentixol is combined with Pinaverium.]
[N05AD05, pipamperone, Pipamperone may increase the central nervous system depressant (CNS depressant) activities of Flupentixol.]
[A03AB14, pipenzolate, Flupentixol may increase the central nervous system depressant (CNS depressant) activities of Pipenzolate.]
[L01DC04, ixabepilone, The risk or severity of myelosuppression can be increased when Flupentixol is combined with Ixabepilone.]
[L01EB02, erlotinib, The risk or severity of QTc prolongation can be increased when Erlotinib is combined with Flupentixol.]
[R03CC07, pirbuterol, The therapeutic efficacy of Pirbuterol can be decreased when used in combination with Flupentixol.]
[A08AA03, diethylpropion, The therapeutic efficacy of Flupentixol can be decreased when used in combination with Diethylpropion.]
[C08CA03, isradipine, The risk or severity of hypotension can be increased when Flupentixol is combined with Isradipine.]
[A03AB11, poldine, Flupentixol may increase the central nervous system depressant (CNS depressant) activities of Poldine.]
[N02BA11, diflunisal, The risk or severity of hypertension can be increased when Diflunisal is combined with Flupentixol.]
[C01AA04, digitoxin, The risk or severity of QTc prolongation can be increased when Digitoxin is combined with Flupentixol.]
[C01AA05, digoxin, The risk or severity of QTc prolongation can be increased when Digoxin is combined with Flupentixol.]
[C02DB01, dihydralazine, Flupentixol may decrease the antihypertensive activities of Dihydralazine.]
[C04AE04, dihydroergocristine, The risk or severity of hypertension can be increased when Flupentixol is combined with Dihydroergocristine.]
[N02CA01, dihydroergotamine, Dihydroergotamine may increase the orthostatic hypotensive, hypotensive, and antihypertensive activities of Flupentixol.]
[N02AA03, hydromorphone, Hydromorphone may increase the central nervous system depressant (CNS depressant) activities of Flupentixol.]
[L04AX04, lenalidomide, The risk or severity of myelosuppression can be increased when Flupentixol is combined with Lenalidomide.]
[J05AE08, atazanavir, The risk or severity of QTc prolongation can be increased when Atazanavir is combined with Flupentixol.]
[B01AC21, treprostinil, The risk or severity of QTc prolongation can be increased when Treprostinil is combined with Flupentixol.]
[D04AB07, pramoxine, Pramocaine may increase the central nervous system depressant (CNS depressant) activities of Flupentixol.]
[C08DB01, diltiazem, The risk or severity of QTc prolongation can be increased when Diltiazem is combined with Flupentixol.]
[R06AA11, dimenhydrinate, The risk or severity of QTc prolongation can be increased when Dimenhydrinate is combined with Flupentixol.]
[M03BX03, pridinol, Pridinol may increase the central nervous system depressant (CNS depressant) activities of Flupentixol.]
[R06AB03, dimethindene, Flupentixol may increase the central nervous system depressant (CNS depressant) activities of Dimetindene.]
[R03CC08, procaterol, The therapeutic efficacy of Procaterol can be decreased when used in combination with Flupentixol.]
[N03AG05, progabide, The therapeutic efficacy of Progabide can be decreased when used in combination with Flupentixol.]
[N02BB04, propyphenazone, The risk or severity of hypertension can be increased when Flupentixol is combined with Propyphenazone.]
[M01AB14, proglumetacin, The risk or severity of hypertension can be increased when Flupentixol is combined with Proglumetacin.]
[R06AA02, diphenhydramine, Flupentixol may increase the sedative activities of Diphenhydramine.]
[A07DA01, diphenoxylate, Diphenoxylate may increase the central nervous system depressant (CNS depressant) activities of Flupentixol.]
[N05CD10, quazepam, Flupentixol may increase the sedative activities of Quazepam.]
[C09AA06, quinapril, Flupentixol may decrease the antihypertensive activities of Quinapril.]
[B01AC07, dipyridamole, The risk or severity of hypotension and syncope can be increased when Dipyridamole is combined with Flupentixol.]
[N06BA11, dexmethylphenidate, The risk or severity of adverse effects can be increased when Flupentixol is combined with Dexmethylphenidate.]
[N06AA23, quinupramine, Quinupramine may increase the central nervous system depressant (CNS depressant) activities of Flupentixol.]
[A03FA02, cisapride, The risk or severity of QTc prolongation can be increased when Cisapride is combined with Flupentixol.]
[C09AA05, ramipril, Flupentixol may decrease the antihypertensive activities of Ramipril.]
[S01XA23, sirolimus, The risk or severity of myelosuppression can be increased when Flupentixol is combined with Sirolimus.]
[N05AL04, remoxipride, Remoxipride may increase the central nervous system depressant (CNS depressant) activities of Flupentixol.]
[R03CC14, reproterol, The therapeutic efficacy of Reproterol can be decreased when used in combination with Flupentixol.]
[C01BA03, disopyramide, The risk or severity of QTc prolongation can be increased when Disopyramide is combined with Flupentixol.]
[P03AA04, disulfiram, The risk or severity of QTc prolongation can be increased when Disulfiram is combined with Flupentixol.]
[N07XX02, riluzole, Riluzole may increase the central nervous system depressant (CNS depressant) activities of Flupentixol.]
[N05AX08, risperidone, Risperidone may increase the orthostatic hypotensive, hypotensive, and antihypertensive activities of Flupentixol.]
[R06AE09, levocetirizine, Levocetirizine may increase the central nervous system depressant (CNS depressant) activities of Flupentixol.]
[N01BB09, ropivacaine, Ropivacaine may increase the central nervous system depressant (CNS depressant) activities of Flupentixol.]
[J01MB01, rosoxacin, The risk or severity of QTc prolongation can be increased when Rosoxacin is combined with Flupentixol.]
[L01EX01, sunitinib, The risk or severity of QTc prolongation can be increased when Sunitinib is combined with Flupentixol.]
[L01XG01, bortezomib, The risk or severity of myelosuppression can be increased when Flupentixol is combined with Bortezomib.]
[G04BE08, tadalafil, The risk or severity of hypotension and syncope can be increased when Tadalafil is combined with Flupentixol.]
[S01BC05, ketorolac, The risk or severity of hypertension can be increased when Ketorolac is combined with Flupentixol.]
[C02KX02, ambrisentan, Flupentixol may decrease the antihypertensive activities of Ambrisentan.]
[C01EB18, ranolazine, The risk or severity of QTc prolongation can be increased when Ranolazine is combined with Flupentixol.]
[N02BA06, salsalate, The risk or severity of hypertension can be increased when Flupentixol is combined with Salsalate.]
[R03AC12, salmeterol, The therapeutic efficacy of Salmeterol can be decreased when used in combination with Flupentixol.]
[C01CA07, dobutamine, The therapeutic efficacy of Dobutamine can be decreased when used in combination with Flupentixol.]
[A03FA03, domperidone, The risk or severity of QTc prolongation can be increased when Domperidone is combined with Flupentixol.]
[C01CA04, dopamine, The risk or severity of hypertension can be increased when Flupentixol is combined with Dopamine.]
[N06AA16, dothiepin, Flupentixol may increase the central nervous system depressant (CNS depressant) activities of Dosulepin.]
[R07AB01, doxapram, The risk or severity of hypertension can be increased when Doxapram is combined with Flupentixol.]
[N06AA12, doxepin, Flupentixol may increase the sedative activities of Doxepin.]
[A06AB06, sennosides, USP, The therapeutic efficacy of Sennosides can be decreased when used in combination with Flupentixol.]
[L01DB01, doxorubicin, The risk or severity of myelosuppression can be increased when Flupentixol is combined with Doxorubicin.]
[R06AA09, doxylamine, Doxylamine may increase the central nervous system depressant (CNS depressant) activities of Flupentixol.]
[N06AB06, sertraline, The risk or severity of adverse effects can be increased when Flupentixol is combined with Sertraline.]
[N01AB08, sevoflurane, Sevoflurane may increase the central nervous system depressant (CNS depressant) activities of Flupentixol.]
[N05AD08, droperidol, The risk or severity of QTc prolongation can be increased when Droperidol is combined with Flupentixol.]
[A08AA10, sibutramine, The risk or severity of adverse effects can be increased when Flupentixol is combined with Sibutramine.]
[V03AG05, sodium phosphate, The therapeutic efficacy of Sodium phosphate, monobasic can be decreased when used in combination with Flupentixol.]
[A12CA02, sodium sulfate, The therapeutic efficacy of Sodium sulfate can be decreased when used in combination with Flupentixol.]
[C09AA11, spirapril, Flupentixol may decrease the antihypertensive activities of Spirapril.]
[N05AL02, sultopride, The risk or severity of QTc prolongation can be increased when Sultopride is combined with Flupentixol.]
[N02CC01, sumatriptan, Sumatriptan may increase the central nervous system depressant (CNS depressant) activities of Flupentixol.]
[C07AB13, talinolol, Talinolol may increase the orthostatic hypotensive activities of Flupentixol.]
[J01MA05, temafloxacin, The risk or severity of QTc prolongation can be increased when Temafloxacin is combined with Flupentixol.]
[L01AX03, temozolomide, The risk or severity of myelosuppression can be increased when Flupentixol is combined with Temozolomide.]
[M01AC02, tenoxicam, The risk or severity of hypertension can be increased when Tenoxicam is combined with Flupentixol.]
[G04CA03, terazosin, Flupentixol may increase the orthostatic hypotensive, hypotensive, and antihypertensive activities of Terazosin.]
[G04BD05, terodiline, The risk or severity of QTc prolongation can be increased when Terodiline is combined with Flupentixol.]
[C07AA16, tertatolol, Tertatolol may increase the orthostatic hypotensive activities of Flupentixol.]
[S01GA02, tetrahydrozoline, The therapeutic efficacy of Tetryzoline can be decreased when used in combination with Flupentixol.]
[M03BX07, tetrazepam, Tetrazepam may increase the central nervous system depressant (CNS depressant) activities of Flupentixol.]
[M03BX05, thiocolchicoside, Thiocolchicoside may increase the central nervous system depressant (CNS depressant) activities of Flupentixol.]
[N05AB05, thiopropazate, Thiopropazate may increase the central nervous system depressant (CNS depressant) activities of Flupentixol.]
[G04BD01, emepronium, Flupentixol may increase the sedative activities of Emepronium.]
[N06AX14, tianeptine, Tianeptine may increase the central nervous system depressant (CNS depressant) activities of Flupentixol.]
[C09AA02, enalapril, Flupentixol may decrease the antihypertensive activities of Enalapril.]
[N05BA23, tofisopam, Tofisopam may increase the central nervous system depressant (CNS depressant) activities of Flupentixol.]
[M01AG02, tolfenamic acid, The risk or severity of hypertension can be increased when Flupentixol is combined with Tolfenamic acid.]
[N06AG03, toloxatone, Toloxatone may increase the central nervous system depressant (CNS depressant) activities of Flupentixol.]
[N06BA09, atomoxetine, The risk or severity of QTc prolongation can be increased when Atomoxetine is combined with Flupentixol.]
[N03AX11, topiramate, The risk or severity of hyperthermia and oligohydrosis can be increased when Flupentixol is combined with Topiramate.]
[L02BA02, toremifene, The risk or severity of QTc prolongation can be increased when Toremifene is combined with Flupentixol.]
[C03CA04, torsemide, Flupentixol may decrease the antihypertensive activities of Torasemide.]
[R01AA09, tramazoline, The risk or severity of hypertension can be increased when Flupentixol is combined with Tramazoline.]
[C09AA10, trandolapril, Flupentixol may decrease the antihypertensive activities of Trandolapril.]
[N05CD11, triazulenone, Flupentixol may increase the sedative activities of Loprazolam.]
[N05CC01, chloral hydrate, Flupentixol may increase the sedative activities of Chloral hydrate.]
[N05CM07, triclofos, Flupentixol may increase the sedative activities of Triclofos.]
[A03AB08, tridihexethyl, Flupentixol may increase the central nervous system depressant (CNS depressant) activities of Tridihexethyl.]
[R06AA10, trimethobenzamide, Trimethobenzamide may increase the central nervous system depressant (CNS depressant) activities of Flupentixol.]
[L02AE04, triptorelin, The risk or severity of QTc prolongation can be increased when Triptorelin is combined with Flupentixol.]
[N04AA12, tropatepine, The therapeutic efficacy of Tropatepine can be decreased when used in combination with Flupentixol.]
[R03CC11, tulobuterol, The therapeutic efficacy of Tulobuterol can be decreased when used in combination with Flupentixol.]
[N01AB04, enflurane, Enflurane may increase the central nervous system depressant (CNS depressant) activities of Flupentixol.]
[C02CA06, urapidil, Flupentixol may increase the orthostatic hypotensive, hypotensive, and antihypertensive activities of Urapidil.]
[J01MA04, enoxacin, The risk or severity of QTc prolongation can be increased when Enoxacin is combined with Flupentixol.]
[N05AL06, veralipride, Veralipride may increase the central nervous system depressant (CNS depressant) activities of Flupentixol.]
[L01CA04, vinorelbine, The risk or severity of myelosuppression can be increased when Flupentixol is combined with Vinorelbine.]
[S01FB02, ephedrine, The therapeutic efficacy of Ephedrine can be decreased when used in combination with Flupentixol.]
[S01GX10, epinastine, Epinastine may increase the central nervous system depressant (CNS depressant) activities of Flupentixol.]
[N06AX16, venlafaxine, The risk or severity of serotonin syndrome can be increased when Flupentixol is combined with Venlafaxine.]
[C01CX07, xamoterol, The therapeutic efficacy of Xamoterol can be decreased when used in combination with Flupentixol.]
[S01GA03, xylometazoline, The therapeutic efficacy of Xylometazoline can be decreased when used in combination with Flupentixol.]
[C08CA12, mepirodipine, The risk or severity of hypotension can be increased when Flupentixol is combined with Barnidipine.]
[S01EA01, epinephrine, The therapeutic efficacy of Epinephrine can be decreased when used in combination with Flupentixol.]
[L01DB03, epirubicin, The risk or severity of myelosuppression can be increased when Flupentixol is combined with Epirubicin.]
[C09AA15, zofenopril, Flupentixol may decrease the antihypertensive activities of Zofenopril.]
[N05CF02, zolpidem, Flupentixol may increase the central nervous system depressant (CNS depressant) activities of Zolpidem.]
[M01AB04, zomepirac, The risk or severity of hypertension can be increased when Flupentixol is combined with Zomepirac.]
[N03AX15, zonisamide, Zonisamide may increase the central nervous system depressant (CNS depressant) activities of Flupentixol.]
[N05CF01, zopiclone, Flupentixol may increase the sedative activities of Zopiclone.]
[N05AX11, zotepine, Zotepine may increase the central nervous system depressant (CNS depressant) activities of Flupentixol.]
[L01XA02, carboplatin, The risk or severity of myelosuppression can be increased when Flupentixol is combined with Carboplatin.]
[C02AC02, guanfacine, The therapeutic efficacy of Guanfacine can be decreased when used in combination with Flupentixol.]
[C01BG01, moricizine, Moricizine may increase the central nervous system depressant (CNS depressant) activities of Flupentixol.]
[G02AB03, ergonovine, The therapeutic efficacy of Ergometrine can be decreased when used in combination with Flupentixol.]
[C04AE01, ergoloid mesylates, USP, Ergoloid mesylate may increase the central nervous system depressant (CNS depressant) activities of Flupentixol.]
[N02CA02, ergotamine, Ergotamine may increase the orthostatic hypotensive, hypotensive, and antihypertensive activities of Flupentixol.]
[N03AG01, valproic acid, The risk or severity of QTc prolongation can be increased when Valproic acid is combined with Flupentixol.]
[S01AA17, erythromycin, The risk or severity of QTc prolongation can be increased when Erythromycin is combined with Flupentixol.]
[N05CD04, estazolam, Flupentixol may increase the sedative activities of Estazolam.]
[C01CA15, gepefrine, The therapeutic efficacy of Flupentixol can be decreased when used in combination with Gepefrine.]
[N05CM08, ethchlorvynol, Flupentixol may increase the sedative activities of Ethchlorvynol.]
[C01BD05, ibutilide, The risk or severity of QTc prolongation can be increased when Ibutilide is combined with Flupentixol.]
[N04AA05, profenamine, The therapeutic efficacy of Profenamine can be decreased when used in combination with Flupentixol.]
[N03AD01, ethosuximide, Ethosuximide may increase the central nervous system depressant (CNS depressant) activities of Flupentixol.]
[N03AB01, ethotoin, Ethotoin may increase the central nervous system depressant (CNS depressant) activities of Flupentixol.]
[M01AC06, meloxicam, The risk or severity of hypertension can be increased when Meloxicam is combined with Flupentixol.]
[S01XA06, ethylmorphine, Ethylmorphine may increase the central nervous system depressant (CNS depressant) activities of Flupentixol.]
[C01CA01, etilefrine, The therapeutic efficacy of Etilefrine can be decreased when used in combination with Flupentixol.]
[N01AX07, etomidate, Flupentixol may increase the sedative activities of Etomidate.]
[L01CB01, etoposide, The risk or severity of myelosuppression can be increased when Flupentixol is combined with Etoposide.]
[N05AE03, sertindole, Sertindole may increase the central nervous system depressant (CNS depressant) activities of Flupentixol.]
[C01BA05, ajmaline, The risk or severity of QTc prolongation can be increased when Ajmaline is combined with Flupentixol.]
[L04AD02, tacrolimus, The risk or severity of myelosuppression can be increased when Flupentixol is combined with Tacrolimus.]
[J01MA08, fleroxacin, The risk or severity of QTc prolongation can be increased when Fleroxacin is combined with Flupentixol.]
[R06AX11, astemizole, The risk or severity of QTc prolongation can be increased when Astemizole is combined with Flupentixol.]
[R06AX12, terfenadine, The risk or severity of QTc prolongation can be increased when Terfenadine is combined with Flupentixol.]
[N06AX12, bupropion, Bupropion may increase the central nervous system depressant (CNS depressant) activities of Flupentixol.]
[N06AB08, fluvoxamine, The risk or severity of adverse effects can be increased when Flupentixol is combined with Fluvoxamine.]
[C01BC08, encainide, The risk or severity of QTc prolongation can be increased when Encainide is combined with Flupentixol.]
[L02AE02, leuprolide, The risk or severity of QTc prolongation can be increased when Leuprolide is combined with Flupentixol.]
[V03AF02, dexrazoxane, The risk or severity of myelosuppression can be increased when Flupentixol is combined with Dexrazoxane.]
[A02BA03, famotidine, The risk or severity of QTc prolongation can be increased when Famotidine is combined with Flupentixol.]
[C08CA02, felodipine, The risk or severity of hypotension can be increased when Flupentixol is combined with Felodipine.]
[C08EA01, fendiline, The risk or severity of QTc prolongation can be increased when Fendiline is combined with Flupentixol.]
[N03AX26, fenfluramine, The therapeutic efficacy of Fenfluramine can be decreased when used in combination with Flupentixol.]
[M01AE04, fenoprofen, The risk or severity of hypertension can be increased when Fenoprofen is combined with Flupentixol.]
[R03CC04, fenoterol, The therapeutic efficacy of Fenoterol can be decreased when used in combination with Flupentixol.]
[N02AB03, fentanyl, Fentanyl may increase the central nervous system depressant (CNS depressant) activities of Flupentixol.]
[R03CC02, albuterol, The therapeutic efficacy of Salbutamol can be decreased when used in combination with Flupentixol.]
[L01BB06, clofarabine, The risk or severity of myelosuppression can be increased when Flupentixol is combined with Clofarabine.]
[L04AA40, cladribine, The risk or severity of myelosuppression can be increased when Flupentixol is combined with Cladribine.]
[G04BD02, flavoxate, Flupentixol may increase the central nervous system depressant (CNS depressant) activities of Flavoxate.]
[C01BC04, flecainide, The risk or severity of QTc prolongation can be increased when Flecainide is combined with Flupentixol.]
[N02BG04, floctafenine, The risk or severity of hypertension can be increased when Flupentixol is combined with Floctafenine.]
[J02AC01, fluconazole, The risk or severity of QTc prolongation can be increased when Fluconazole is combined with Flupentixol.]
[J02AX01, flucytosine, The risk or severity of myelosuppression can be increased when Flupentixol is combined with Flucytosine.]
[N07CA03, flunarizine, Flunarizine may increase the central nervous system depressant (CNS depressant) activities of Flupentixol.]
[N05CD03, flunitrazepam, Flupentixol may increase the sedative activities of Flunitrazepam.]
[V03AZ01, ethanol, Flupentixol may increase the central nervous system depressant (CNS depressant) activities of Ethanol.]
[L01BC09, floxuridine, The risk or severity of myelosuppression can be increased when Flupentixol is combined with Floxuridine.]
[L01BC02, fluorouracil, The risk or severity of QTc prolongation can be increased when Fluorouracil is combined with Flupentixol.]
[N06AB03, fluoxetine, The risk or severity of QTc prolongation can be increased when Fluoxetine is combined with Flupentixol.]
[J01MB04, pipemidic acid, The risk or severity of QTc prolongation can be increased when Pipemidic acid is combined with Flupentixol.]
[N07XX04, sodium oxybate, Flupentixol may increase the central nervous system depressant (CNS depressant) activities of Sodium oxybate.]
[M01AG01, mefenamic acid, The risk or severity of hypertension can be increased when Mefenamic acid is combined with Flupentixol.]
[N05AB02, fluphenazine, Fluphenazine may increase the central nervous system depressant (CNS depressant) activities of Flupentixol.]
[N05CD01, flurazepam, Flupentixol may increase the sedative activities of Flurazepam.]
[S01BC04, flurbiprofen, The risk or severity of hypertension can be increased when Flurbiprofen is combined with Flupentixol.]
[N05AG01, fluspirilene, The risk or severity of QTc prolongation can be increased when Fluspirilene is combined with Flupentixol.]
[N06BX17, adrafinil, The therapeutic efficacy of Adrafinil can be decreased when used in combination with Flupentixol.]
[M03AA01, alcuronium, Alcuronium may increase the central nervous system depressant (CNS depressant) activities of Flupentixol.]
[G01AX06, furazolidone, Furazolidone may increase the central nervous system depressant (CNS depressant) activities of Flupentixol.]
[C03CA01, furosemide, Flupentixol may decrease the antihypertensive activities of Furosemide.]
[N05CF04, eszopiclone, The risk or severity of CNS depression can be increased when Flupentixol is combined with Eszopiclone.]
[N05AL05, amisulpride, Flupentixol may increase the antipsychotic activities of Amisulpride.]
[N06DA04, galantamine, The risk or severity of QTc prolongation can be increased when Galantamine is combined with Flupentixol.]
[M03AC02, gallamine, Gallamine may increase the central nervous system depressant (CNS depressant) activities of Flupentixol.]
[C08DA02, gallopamil, The risk or severity of hypotension can be increased when Flupentixol is combined with Gallopamil.]
[N03AA04, barbexaclone, Flupentixol may increase the sedative activities of Barbexaclone.]
[N06AX08, bifemelane, Bifemelane may increase the central nervous system depressant (CNS depressant) activities of Flupentixol.]
[J01XA03, telavancin, The risk or severity of QTc prolongation can be increased when Telavancin is combined with Flupentixol.]
[L02BX02, degarelix, The risk or severity of QTc prolongation can be increased when Degarelix is combined with Flupentixol.]
[L01EA02, dasatinib, The risk or severity of myelosuppression can be increased when Flupentixol is combined with Dasatinib.]
[N04BC06, cabergoline, The therapeutic efficacy of Cabergoline can be decreased when used in combination with Flupentixol.]
[N03AD03, methsuximide, Methsuximide may increase the central nervous system depressant (CNS depressant) activities of Flupentixol.]
[N01AH02, alfentanil, Alfentanil may increase the central nervous system depressant (CNS depressant) activities of Flupentixol.]
[L01EH01, lapatinib, The risk or severity of QTc prolongation can be increased when Lapatinib is combined with Flupentixol.]
[H04AA01, glucagon, Flupentixol may increase the gastrointestinal motility reducing activities of Glucagon.]
[N05CM18, dexmedetomidine, Flupentixol may increase the sedative activities of Dexmedetomidine.]
[N05CE01, glutethimide, Flupentixol may increase the sedative activities of Glutethimide.]
[A06AX01, glycerin, The therapeutic efficacy of Glycerin can be decreased when used in combination with Flupentixol.]
[C05AE01, nitroglycerin, Flupentixol may decrease the antihypertensive activities of Nitroglycerin.]
[C01BD04, dofetilide, The risk or severity of QTc prolongation can be increased when Dofetilide is combined with Flupentixol.]
[C02CA04, doxazosin, Doxazosin may increase the orthostatic hypotensive, hypotensive, and antihypertensive activities of Flupentixol.]
[L01EX02, sorafenib, The risk or severity of myelosuppression can be increased when Flupentixol is combined with Sorafenib.]
[C07AB09, esmolol, Esmolol may increase the orthostatic hypotensive activities of Flupentixol.]
[B01AA12, fluindione, The risk or severity of adverse effects can be increased when Flupentixol is combined with Fluindione.]
[C09AA09, fosinopril, Flupentixol may decrease the antihypertensive activities of Fosinopril.]
[S01EX01, guanethidine, Flupentixol may decrease the antihypertensive activities of Guanethidine.]
[L02AE03, goserelin, The risk or severity of QTc prolongation can be increased when Goserelin is combined with Flupentixol.]
[P01BX01, halofantrine, The risk or severity of QTc prolongation can be increased when Halofantrine is combined with Flupentixol.]
[N05AD01, haloperidol, The risk or severity of QTc prolongation can be increased when Haloperidol is combined with Flupentixol.]
[N01AB01, halothane, Halothane may increase the central nervous system depressant (CNS depressant) activities of Flupentixol.]
[L02AE05, histrelin, The risk or severity of QTc prolongation can be increased when Histrelin is combined with Flupentixol.]
[N05AH04, quetiapine, The risk or severity of QTc prolongation can be increased when Quetiapine is combined with Flupentixol.]
[N02CX03, iprazochrome, Iprazochrome may increase the central nervous system depressant (CNS depressant) activities of Flupentixol.]
[L01CE02, irinotecan, The risk or severity of myelosuppression can be increased when Flupentixol is combined with Irinotecan.]
[N05CA21, allobarbital, Flupentixol may increase the sedative activities of Allobarbital.]
[C09CA01, losartan, The risk or severity of QTc prolongation can be increased when Losartan is combined with Flupentixol.]
[B05CB03, magnesium citrate, The therapeutic efficacy of Magnesium citrate can be decreased when used in combination with Flupentixol.]
[A07EC02, mesalamine, The risk or severity of hypertension can be increased when Mesalazine is combined with Flupentixol.]
[A12CD02, sodium monofluorophosphate, The therapeutic efficacy of Sodium fluorophosphate can be decreased when used in combination with Flupentixol.]
[L01XX03, altretamine, The risk or severity of myelosuppression can be increased when Flupentixol is combined with Altretamine.]
[N05CA16, hexobarbital, Flupentixol may increase the sedative activities of Hexobarbital.]
[R03CC05, hexoprenaline, The therapeutic efficacy of Hexoprenaline can be decreased when used in combination with Flupentixol.]
[C08CA10, nilvadipine, The risk or severity of QTc prolongation can be increased when Nilvadipine is combined with Flupentixol.]
[M02AA26, nimesulide, The risk or severity of hypotension can be increased when Flupentixol is combined with Nimesulide.]
[R06AE06, oxatomide, The risk or severity of QTc prolongation can be increased when Oxatomide is combined with Flupentixol.]
[C09AA04, perindopril, Flupentixol may decrease the antihypertensive activities of Perindopril.]
[C02DB02, hydralazine, Flupentixol may decrease the antihypertensive activities of Hydralazine.]
[C03AA03, hydrochlorothiazide, The risk or severity of QTc prolongation can be increased when Hydrochlorothiazide is combined with Flupentixol.]
[R05DA03, hydrocodone, Flupentixol may increase the central nervous system depressant (CNS depressant) activities of Hydrocodone.]
[C03AA02, hydroflumethiazide, Flupentixol may decrease the antihypertensive activities of Hydroflumethiazide.]
[G04BD06, propiverine, Flupentixol may increase the orthostatic hypotensive, hypotensive, and antihypertensive activities of Propiverine.]
[P01BA02, hydroxychloroquine, The risk or severity of QTc prolongation can be increased when Hydroxychloroquine is combined with Flupentixol.]
[N05AX07, prothipendyl, Prothipendyl may increase the central nervous system depressant (CNS depressant) activities of Flupentixol.]
[L01XX05, hydroxyurea, The risk or severity of myelosuppression can be increased when Flupentixol is combined with Hydroxyurea.]
[N05BB01, hydroxyzine, The risk or severity of QTc prolongation can be increased when Flupentixol is combined with Hydroxyzine.]
[C02AC06, rilmenidine, The therapeutic efficacy of Rilmenidine can be decreased when used in combination with Flupentixol.]
[R02AX02, ibuprofen, The risk or severity of hypertension can be increased when Flupentixol is combined with Ibuprofen.]
[B05CB02, sodium citrate, Flupentixol may increase the neurotoxic activities of Sodium citrate.]
[L01DB06, idarubicin, The risk or severity of myelosuppression can be increased when Flupentixol is combined with Idarubicin.]
[A06AD21, sodium tartrate, The therapeutic efficacy of Sodium tartrate can be decreased when used in combination with Flupentixol.]
[L01AA06, ifosfamide, The risk or severity of myelosuppression can be increased when Flupentixol is combined with Ifosfamide.]
[N01AH03, sufentanil, Sufentanil may increase the central nervous system depressant (CNS depressant) activities of Flupentixol.]
[N06AA02, imipramine, The serum concentration of Imipramine can be increased when it is combined with Flupentixol.]
[L01CD01, paclitaxel, The risk or severity of myelosuppression can be increased when Flupentixol is combined with Paclitaxel.]
[H01BA04, terlipressin, The risk or severity of QTc prolongation can be increased when Terlipressin is combined with Flupentixol.]
[M03BX02, tizanidine, The therapeutic efficacy of Tizanidine can be decreased when used in combination with Flupentixol.]
[L01CE01, topotecan, The risk or severity of myelosuppression can be increased when Flupentixol is combined with Topotecan.]
[C03BA11, indapamide, The risk or severity of QTc prolongation can be increased when Indapamide is combined with Flupentixol.]
[S01BC01, indomethacin, The risk or severity of myelosuppression can be increased when Flupentixol is combined with Indomethacin.]
[C02CA02, indoramin, Flupentixol may increase the orthostatic hypotensive, hypotensive, and antihypertensive activities of Indoramin.]
[L03AB04, interferon alfa-2a, The risk or severity of myelosuppression can be increased when Flupentixol is combined with Interferon alfa-2a.]
[L03AB05, interferon alfa-2b, The risk or severity of myelosuppression can be increased when Flupentixol is combined with Interferon alfa-2b.]
[N06AX17, milnacipran, The risk or severity of adverse effects can be increased when Flupentixol is combined with Milnacipran.]
[A03AA30, piperidolate, Flupentixol may increase the central nervous system depressant (CNS depressant) activities of Piperidolate.]
[N01BB08, articaine, Articaine may increase the central nervous system depressant (CNS depressant) activities of Flupentixol.]
[N05BA12, alprazolam, Flupentixol may increase the sedative activities of Alprazolam.]
[N05CH02, ramelteon, Flupentixol may increase the sedative activities of Ramelteon.]
[R06AE01, buclizine, Flupentixol may increase the central nervous system depressant (CNS depressant) activities of Buclizine.]
[L01XX35, anagrelide, The risk or severity of QTc prolongation can be increased when Anagrelide is combined with Flupentixol.]
[C07AA01, alprenolol, Alprenolol may increase the orthostatic hypotensive activities of Flupentixol.]
[L03AB09, interferon alfacon-1, The risk or severity of myelosuppression can be increased when Flupentixol is combined with Interferon alfacon-1.]
[J05AF04, stavudine, Stavudine may increase the neurotoxic activities of Flupentixol.]
[N06AA13, iprindole, Iprindole may increase the central nervous system depressant (CNS depressant) activities of Flupentixol.]
[N06AF05, iproniazid, Iproniazid may increase the central nervous system depressant (CNS depressant) activities of Flupentixol.]
[N05AA07, chlorproethazine, Chlorproethazine may increase the central nervous system depressant (CNS depressant) activities of Flupentixol.]
[N06AF01, isocarboxazid, Isocarboxazid may increase the central nervous system depressant (CNS depressant) activities of Flupentixol.]
[R03CC06, isoetharine, The therapeutic efficacy of Isoetharine can be decreased when used in combination with Flupentixol.]
[C09AA16, imidapril, Flupentixol may decrease the antihypertensive activities of Imidapril.]
[N01AB06, isoflurane, Isoflurane may increase the central nervous system depressant (CNS depressant) activities of Flupentixol.]
[N04BX02, entacapone, The therapeutic efficacy of Entacapone can be decreased when used in combination with Flupentixol.]
[J04AC01, isoniazid, The risk or severity of serotonin syndrome can be increased when Flupentixol is combined with Isoniazid.]
[R03CB01, isoproterenol, The therapeutic efficacy of Isoprenaline can be decreased when used in combination with Flupentixol.]
[C04AA01, isoxsuprine, The therapeutic efficacy of Isoxsuprine can be decreased when used in combination with Flupentixol.]
[N06AX18, reboxetine, Reboxetine may increase the central nervous system depressant (CNS depressant) activities of Flupentixol.]
[N01AX03, ketamine, Ketamine may increase the central nervous system depressant (CNS depressant) activities of Flupentixol.]
[C02KD01, ketanserin, Ketanserin may increase the central nervous system depressant (CNS depressant) activities of Flupentixol.]
[J02AB02, ketoconazole, The risk or severity of QTc prolongation can be increased when Ketoconazole is combined with Flupentixol.]
[N05AH03, olanzapine, Olanzapine may increase the orthostatic hypotensive, hypotensive, and antihypertensive activities of Flupentixol.]
[M02AA10, ketoprofen, The risk or severity of hypertension can be increased when Flupentixol is combined with Ketoprofen.]
[R06AX25, mizolastine, The risk or severity of QTc prolongation can be increased when Mizolastine is combined with Flupentixol.]
[C01CA22, arbutamine, The therapeutic efficacy of Arbutamine can be decreased when used in combination with Flupentixol.]
[N04BC09, rotigotine, The therapeutic efficacy of Rotigotine can be decreased when used in combination with Flupentixol.]
[J01MB02, nalidixic acid, The risk or severity of QTc prolongation can be increased when Nalidixic acid is combined with Flupentixol.]
[C07AG01, labetalol, Labetalol may increase the orthostatic hypotensive, hypotensive, and antihypertensive activities of Flupentixol.]
[N04BB01, amantadine, The therapeutic efficacy of Amantadine can be decreased when used in combination with Flupentixol.]
[C02AA05, deserpidine, Flupentixol may decrease the antihypertensive activities of Deserpidine.]
[A06AD11, lactulose, The therapeutic efficacy of Lactulose can be decreased when used in combination with Flupentixol.]
[A06AX03, lubiprostone, The therapeutic efficacy of Lubiprostone can be decreased when used in combination with Flupentixol.]
[N03AX18, lacosamide, Lacosamide may increase the central nervous system depressant (CNS depressant) activities of Flupentixol.]
[L01DC03, mitomycin, The risk or severity of myelosuppression can be increased when Flupentixol is combined with Mitomycin.]
[N04BA01, levodopa, The therapeutic efficacy of Levodopa can be decreased when used in combination with Flupentixol.]
[S02DA01, lidocaine, Lidocaine may increase the central nervous system depressant (CNS depressant) activities of Flupentixol.]
[C08EX01, lidoflazine, The risk or severity of hypotension can be increased when Flupentixol is combined with Lidoflazine.]
[J01FF02, lincomycin, Flupentixol may increase the neurotoxic activities of Lincomycin.]
[N02CA07, lisuride, The therapeutic efficacy of Lisuride can be decreased when used in combination with Flupentixol.]
[N06AA07, lofepramine, Lofepramine may increase the central nervous system depressant (CNS depressant) activities of Flupentixol.]
[L01AD02, lomustine, The risk or severity of myelosuppression can be increased when Flupentixol is combined with Lomustine.]
[A07DA03, loperamide, The risk or severity of QTc prolongation can be increased when Loperamide is combined with Flupentixol.]
[N05BA06, lorazepam, Flupentixol may increase the sedative activities of Lorazepam.]
[N05AH01, loxapine, Loxapine may increase the central nervous system depressant (CNS depressant) activities of Flupentixol.]
[L01EG01, temsirolimus, The risk or severity of myelosuppression can be increased when Flupentixol is combined with Temsirolimus.]
[G04BX01, magnesium hydroxide, The therapeutic efficacy of Magnesium hydroxide can be decreased when used in combination with Flupentixol.]
[A12CC10, magnesium oxide, The therapeutic efficacy of Magnesium oxide can be decreased when used in combination with Flupentixol.]
[V04CC02, magnesium sulfate, The therapeutic efficacy of Flupentixol can be increased when used in combination with Magnesium sulfate.]
[L01EA03, nilotinib, The risk or severity of QTc prolongation can be increased when Nilotinib is combined with Flupentixol.]
[N06AA21, maprotiline, Flupentixol may increase the central nervous system depressant (CNS depressant) activities of Maprotiline.]
[A08AA05, mazindol, Mazindol may increase the central nervous system depressant (CNS depressant) activities of Flupentixol.]
[C02BB01, mecamylamine, Flupentixol may decrease the antihypertensive activities of Mecamylamine.]
[L01AA05, mechlorethamine, The risk or severity of myelosuppression can be increased when Flupentixol is combined with Mechlorethamine.]
[R06AE05, meclizine, Meclizine may increase the central nervous system depressant (CNS depressant) activities of Flupentixol.]
[M02AA18, meclofenamic acid, The risk or severity of hypertension can be increased when Flupentixol is combined with Meclofenamic acid.]
[N05BA03, medazepam, Flupentixol may increase the sedative activities of Medazepam.]
[A06AB07, cascara sagrada, The therapeutic efficacy of Frangula purshiana bark can be decreased when used in combination with Flupentixol.]
[P01BC02, mefloquine, The risk or severity of QTc prolongation can be increased when Mefloquine is combined with Flupentixol.]
[N05CH01, melatonin, Flupentixol may increase the sedative activities of Melatonin.]
[L01AA03, melphalan, The risk or severity of myelosuppression can be increased when Flupentixol is combined with Melphalan.]
[N06DX01, memantine, The therapeutic efficacy of Memantine can be decreased when used in combination with Flupentixol.]
[N02AB02, meperidine, Meperidine may increase the central nervous system depressant (CNS depressant) activities of Flupentixol.]
[C01CA11, mephentermine, The therapeutic efficacy of Flupentixol can be decreased when used in combination with Mephentermine.]
[N03AB04, mephenytoin, Mephenytoin may increase the central nervous system depressant (CNS depressant) activities of Flupentixol.]
[N03AA01, mephobarbital, Flupentixol may increase the sedative activities of Methylphenobarbital.]
[N01BB03, mepivacaine, Mepivacaine may increase the central nervous system depressant (CNS depressant) activities of Flupentixol.]
[N05BC01, meprobamate, Flupentixol may increase the sedative activities of Meprobamate.]
[N02AX05, meptazinol, Meptazinol may increase the central nervous system depressant (CNS depressant) activities of Flupentixol.]
[N05AC03, mesoridazine, The risk or severity of QTc prolongation can be increased when Mesoridazine is combined with Flupentixol.]
[N05AX13, paliperidone, The risk or severity of QTc prolongation can be increased when Paliperidone is combined with Flupentixol.]
[C01CA09, metaraminol, The therapeutic efficacy of Metaraminol can be decreased when used in combination with Flupentixol.]
[A04AA04, dolasetron, The risk or severity of QTc prolongation can be increased when Dolasetron is combined with Flupentixol.]
[N07BC02, methadone, The risk or severity of adverse effects can be increased when Methadone is combined with Flupentixol.]
[N06BA03, methamphetamine, The therapeutic efficacy of Flupentixol can be decreased when used in combination with Metamfetamine.]
[A03AB07, methantheline, Flupentixol may increase the central nervous system depressant (CNS depressant) activities of Methantheline.]
[R06AC05, methapyrilene, Flupentixol may increase the sedative activities of Methapyrilene.]
[N05CM01, methaqualone, Flupentixol may increase the sedative activities of Methaqualone.]
[N03AA30, metharbital, Metharbital may increase the central nervous system depressant (CNS depressant) activities of Flupentixol.]
[G02CB05, metergoline, Metergoline may increase the central nervous system depressant (CNS depressant) activities of Flupentixol.]
[H03BB02, methimazole, The risk or severity of myelosuppression can be increased when Flupentixol is combined with Methimazole.]
[L01BA04, pemetrexed, The risk or severity of myelosuppression can be increased when Flupentixol is combined with Pemetrexed.]
[M03BA03, methocarbamol, Methocarbamol may increase the central nervous system depressant (CNS depressant) activities of Flupentixol.]
[N05CA15, methohexital, Flupentixol may increase the sedative activities of Methohexital.]
[N02BG08, ziconotide, The risk or severity of CNS depression can be increased when Flupentixol is combined with Ziconotide.]
[L04AX03, methotrexate, The risk or severity of myelosuppression can be increased when Flupentixol is combined with Methotrexate.]
[N05AA02, methotrimeprazine, Flupentixol may increase the central nervous system depressant (CNS depressant) activities of Methotrimeprazine.]
[C01CA10, methoxamine, The therapeutic efficacy of Methoxamine can be decreased when used in combination with Flupentixol.]
[N02BG09, methoxyflurane, Methoxyflurane may increase the central nervous system depressant (CNS depressant) activities of Flupentixol.]
[A06AC06, methylcellulose, The therapeutic efficacy of Methylcellulose can be decreased when used in combination with Flupentixol.]
[C02AB01, methyldopa, The therapeutic efficacy of Methyldopa can be decreased when used in combination with Flupentixol.]
[V04CG05, methylene blue, Flupentixol may increase the serotonergic activities of Methylene blue.]
[G02AB01, methylergonovine, The risk or severity of hypertension can be increased when Methylergometrine is combined with Flupentixol.]
[N06BA04, methylphenidate, The risk or severity of adverse effects can be increased when Flupentixol is combined with Methylphenidate.]
[N03AF03, rufinamide, The risk or severity of adverse effects can be increased when Rufinamide is combined with Flupentixol.]
[N05CE02, methyprylon, Flupentixol may increase the sedative activities of Methyprylon.]
[N02CA04, methysergide, Methysergide may increase the central nervous system depressant (CNS depressant) activities of Flupentixol.]
[A03FA01, metoclopramide, The risk or severity of extrapyramidal symptoms can be increased when Flupentixol is combined with Metoclopramide.]
[C03BA08, metolazone, Flupentixol may decrease the antihypertensive activities of Metolazone.]
[C07AB02, metoprolol, Metoprolol may increase the orthostatic hypotensive activities of Flupentixol.]
[P01AB01, metronidazole, The risk or severity of QTc prolongation can be increased when Metronidazole is combined with Flupentixol.]
[N06AX03, mianserin, Mianserin may increase the anticholinergic activities of Flupentixol.]
[N02BB03, aminopyrine, The risk or severity of hypertension can be increased when Flupentixol is combined with Aminophenazone.]
[N05CD08, midazolam, Flupentixol may increase the sedative activities of Midazolam.]
[C01CA17, midodrine, The therapeutic efficacy of Midodrine can be decreased when used in combination with Flupentixol.]
[G03XB01, mifepristone, The risk or severity of QTc prolongation can be increased when Mifepristone is combined with Flupentixol.]
[A06AA01, mineral oil, The therapeutic efficacy of Mineral oil can be decreased when used in combination with Flupentixol.]
[C09CA03, valsartan, Flupentixol may decrease the antihypertensive activities of Valsartan.]
[J01AA08, minocycline, Minocycline may increase the central nervous system depressant (CNS depressant) activities of Flupentixol.]
[D11AX01, minoxidil, Flupentixol may decrease the antihypertensive activities of Minoxidil.]
[L01DB07, mitoxantrone, The risk or severity of myelosuppression can be increased when Flupentixol is combined with Mitoxantrone.]
[N06BA12, lisdexamfetamine, The therapeutic efficacy of Flupentixol can be decreased when used in combination with Lisdexamfetamine.]
[N05AE02, molindone, Molindone may increase the central nervous system depressant (CNS depressant) activities of Flupentixol.]
[L03AC01, aldesleukin, The risk or severity of myelosuppression can be increased when Flupentixol is combined with Aldesleukin.]
[C01BD01, amiodarone, The risk or severity of QTc prolongation can be increased when Amiodarone is combined with Flupentixol.]
[N06AA09, amitriptyline, The risk or severity of QTc prolongation can be increased when Amitriptyline is combined with Flupentixol.]
[N02AA01, morphine, Morphine may increase the central nervous system depressant (CNS depressant) activities of Flupentixol.]
[A04AA05, palonosetron, Palonosetron may increase the central nervous system depressant (CNS depressant) activities of Flupentixol.]
[L01EX03, pazopanib, The risk or severity of QTc prolongation can be increased when Pazopanib is combined with Flupentixol.]
[M03AC03, vecuronium, Vecuronium may increase the central nervous system depressant (CNS depressant) activities of Flupentixol.]
[N05CA02, amobarbital, Flupentixol may increase the sedative activities of Amobarbital.]
[P01BA06, amodiaquine, The risk or severity of QTc prolongation can be increased when Amodiaquine is combined with Flupentixol.]
[G04CA04, silodosin, Flupentixol may increase the orthostatic hypotensive, hypotensive, and antihypertensive activities of Silodosin.]
[N06AA17, amoxapine, Amoxapine may increase the orthostatic hypotensive, hypotensive, and antihypertensive activities of Flupentixol.]
[N03AB05, fosphenytoin, Fosphenytoin may increase the central nervous system depressant (CNS depressant) activities of Flupentixol.]
[L03AB08, interferon beta-1b, The risk or severity of myelosuppression can be increased when Flupentixol is combined with Interferon beta-1b.]
[C07AA12, nadolol, Nadolol may increase the orthostatic hypotensive activities of Flupentixol.]
[N04BC04, ropinirole, The therapeutic efficacy of Ropinirole can be decreased when used in combination with Flupentixol.]
[C04AX21, nafronyl, Naftidrofuryl may increase the central nervous system depressant (CNS depressant) activities of Flupentixol.]
[N02AF02, nalbuphine, Nalbuphine may increase the central nervous system depressant (CNS depressant) activities of Flupentixol.]
[N07BB04, naltrexone, The risk or severity of serotonin syndrome can be increased when Naltrexone is combined with Flupentixol.]
[S01GA01, naphazoline, The therapeutic efficacy of Naphazoline can be decreased when used in combination with Flupentixol.]
[N06BA01, amphetamine, The therapeutic efficacy of Flupentixol can be decreased when used in combination with Amphetamine.]
[M02AA12, naproxen, The risk or severity of hypertension can be increased when Naproxen is combined with Flupentixol.]
[N06AX21, duloxetine, The risk or severity of adverse effects can be increased when Flupentixol is combined with Duloxetine.]
[N04BX01, tolcapone, The therapeutic efficacy of Tolcapone can be decreased when used in combination with Flupentixol.]
[L01CD02, docetaxel, The risk or severity of myelosuppression can be increased when Flupentixol is combined with Docetaxel.]
[S03AA01, neomycin, Flupentixol may increase the neurotoxic activities of Neomycin.]
[N01AH06, remifentanil, Flupentixol may increase the sedative activities of Remifentanil.]
[C01CX08, levosimendan, The risk or severity of QTc prolongation can be increased when Levosimendan is combined with Flupentixol.]
[N05AX14, iloperidone, The risk or severity of QTc prolongation can be increased when Iloperidone is combined with Flupentixol.]
[N06AX23, desvenlafaxine, The risk or severity of adverse effects can be increased when Flupentixol is combined with Desvenlafaxine.]
[C09CA07, telmisartan, Flupentixol may decrease the antihypertensive activities of Telmisartan.]
[L01XX01, amsacrine, The risk or severity of myelosuppression can be increased when Flupentixol is combined with Amsacrine.]
[N06AF02, nialamide, Nialamide may increase the central nervous system depressant (CNS depressant) activities of Flupentixol.]
[C08CA04, nicardipine, Nicardipine may increase the orthostatic hypotensive, hypotensive, and antihypertensive activities of Flupentixol.]
[C04AE02, nicergoline, Nicergoline may increase the orthostatic hypotensive, hypotensive, and antihypertensive activities of Flupentixol.]
[N07BA01, nicotine, The risk or severity of Tachycardia can be increased when Nicotine is combined with Flupentixol.]
[C08CA05, nifedipine, The risk or severity of QTc prolongation can be increased when Nifedipine is combined with Flupentixol.]
[M02AA17, niflumic acid, The risk or severity of hypertension can be increased when Flupentixol is combined with Niflumic acid.]
[C08CA06, nimodipine, The risk or severity of QTc prolongation can be increased when Nimodipine is combined with Flupentixol.]
[C08CA07, nisoldipine, The risk or severity of hypotension can be increased when Flupentixol is combined with Nisoldipine.]
[N05CD02, nitrazepam, Flupentixol may increase the sedative activities of Nitrazepam.]
[C08CA08, nitrendipine, The risk or severity of hypotension can be increased when Flupentixol is combined with Nitrendipine.]
[N05CF03, zaleplon, Flupentixol may increase the sedative activities of Zaleplon.]
[N04BC05, pramipexole, The therapeutic efficacy of Pramipexole can be decreased when used in combination with Flupentixol.]
[C02DD01, nitroprusside, Flupentixol may decrease the antihypertensive activities of Nitroprusside.]
[N01AX13, nitrous oxide, Nitrous oxide may increase the central nervous system depressant (CNS depressant) activities of Flupentixol.]
[N06AX04, nomifensine, Nomifensine may increase the central nervous system depressant (CNS depressant) activities of Flupentixol.]
[C01CA03, norepinephrine, The therapeutic efficacy of Norepinephrine can be decreased when used in combination with Flupentixol.]
[S01AE02, norfloxacin, The risk or severity of QTc prolongation can be increased when Norfloxacin is combined with Flupentixol.]
[C02KX01, bosentan, Flupentixol may decrease the antihypertensive activities of Bosentan.]
[N06AA10, nortriptyline, Nortriptyline may increase the orthostatic hypotensive, hypotensive, and antihypertensive activities of Flupentixol.]
[G02CA02, nylidrin, The therapeutic efficacy of Nylidrin can be decreased when used in combination with Flupentixol.]
[H01CB02, octreotide, The risk or severity of QTc prolongation can be increased when Octreotide is combined with Flupentixol.]
[S02AA16, ofloxacin, The risk or severity of QTc prolongation can be increased when Ofloxacin is combined with Flupentixol.]
[N06AA05, opipramol, Opipramol may increase the central nervous system depressant (CNS depressant) activities of Flupentixol.]
[N02AA02, opium, Opium may increase the central nervous system depressant (CNS depressant) activities of Flupentixol.]
[R03CB03, metaproterenol, The therapeutic efficacy of Orciprenaline can be decreased when used in combination with Flupentixol.]
[G02CB04, quinagolide, The therapeutic efficacy of Quinagolide can be decreased when used in combination with Flupentixol.]
[G04CA02, tamsulosin, Tamsulosin may increase the orthostatic hypotensive, hypotensive, and antihypertensive activities of Flupentixol.]
[N05BA04, oxazepam, Flupentixol may increase the sedative activities of Oxazepam.]
[J01MB05, oxolinic acid, The risk or severity of QTc prolongation can be increased when Oxolinic acid is combined with Flupentixol.]
[C07AA02, oxprenolol, Oxprenolol may increase the orthostatic hypotensive activities of Flupentixol.]
[N02AA05, oxycodone, Oxycodone may increase the central nervous system depressant (CNS depressant) activities of Flupentixol.]
[C01DX03, oxyfedrine, The therapeutic efficacy of Oxyfedrine can be decreased when used in combination with Flupentixol.]
[S01GA04, oxymetazoline, The therapeutic efficacy of Oxymetazoline can be decreased when used in combination with Flupentixol.]
[N02AA11, oxymorphone, Oxymorphone may increase the central nervous system depressant (CNS depressant) activities of Flupentixol.]
[N05AE01, oxypertine, Oxypertine may increase the central nervous system depressant (CNS depressant) activities of Flupentixol.]
[S01BC02, oxyphenbutazone, The risk or severity of hypertension can be increased when Flupentixol is combined with Oxyphenbutazone.]
[A03AB03, oxyphenonium, Flupentixol may increase the central nervous system depressant (CNS depressant) activities of Oxyphenonium.]
[H01BB02, oxytocin, The risk or severity of QTc prolongation can be increased when Oxytocin is combined with Flupentixol.]
[N05AH05, asenapine, The risk or severity of QTc prolongation can be increased when Asenapine is combined with Flupentixol.]
[N02AX06, tapentadol, Tapentadol may increase the central nervous system depressant (CNS depressant) activities of Flupentixol.]
[M03AC01, pancuronium, Flupentixol may increase the central nervous system depressant (CNS depressant) activities of Pancuronium.]
[G04BE02, papaverine, The risk or severity of QTc prolongation can be increased when Papaverine is combined with Flupentixol.]
[N05CC05, paraldehyde, Flupentixol may increase the sedative activities of Paraldehyde.]
[C02KC01, pargyline, Pargyline may increase the central nervous system depressant (CNS depressant) activities of Flupentixol.]
[J01MA03, pefloxacin, The risk or severity of QTc prolongation can be increased when Pefloxacin is combined with Flupentixol.]
[G04BD11, fesoterodine, Flupentixol may increase the central nervous system depressant (CNS depressant) activities of Fesoterodine.]
[C07AA23, penbutolol, Penbutolol may increase the orthostatic hypotensive activities of Flupentixol.]
[N05AG03, penfluridol, The risk or severity of QTc prolongation can be increased when Penfluridol is combined with Flupentixol.]
[M01CC01, penicillamine, The risk or severity of myelosuppression can be increased when Flupentixol is combined with Penicillamine.]
[N02AD01, pentazocine, Pentazocine may increase the central nervous system depressant (CNS depressant) activities of Flupentixol.]
[N05CA01, pentobarbital, Flupentixol may increase the sedative activities of Pentobarbital.]
[L01XX08, pentostatin, The risk or severity of myelosuppression can be increased when Flupentixol is combined with Pentostatin.]
[N05AB10, perazine, Perazine may increase the central nervous system depressant (CNS depressant) activities of Flupentixol.]
[N04BC02, pergolide, The therapeutic efficacy of Pergolide can be decreased when used in combination with Flupentixol.]
[C08EX02, perhexiline, The risk or severity of hypotension can be increased when Flupentixol is combined with Perhexiline.]
[N05AB03, perphenazine, Perphenazine may increase the central nervous system depressant (CNS depressant) activities of Flupentixol.]
[N02AD02, phenazocine, Phenazocine may increase the central nervous system depressant (CNS depressant) activities of Flupentixol.]
[N06AF03, phenelzine, Phenelzine may increase the central nervous system depressant (CNS depressant) activities of Flupentixol.]
[B01AA02, phenindione, The risk or severity of adverse effects can be increased when Flupentixol is combined with Phenindione.]
[R06AB05, pheniramine, The risk or severity of QTc prolongation can be increased when Pheniramine is combined with Flupentixol.]
[N03AA02, phenobarbital, Flupentixol may increase the sedative activities of Phenobarbital.]
[A06AB01, oxyphenisatin, The therapeutic efficacy of Oxyphenisatin can be decreased when used in combination with Flupentixol.]
[N01AH04, phenoperidine, Phenoperidine may increase the central nervous system depressant (CNS depressant) activities of Flupentixol.]
[C04AX02, phenoxybenzamine, Flupentixol may increase the orthostatic hypotensive, hypotensive, and antihypertensive activities of Phenoxybenzamine.]
[B01AA04, phenprocoumon, The risk or severity of adverse effects can be increased when Flupentixol is combined with Phenprocoumon.]
[A08AA01, phentermine, The therapeutic efficacy of Flupentixol can be decreased when used in combination with Phentermine.]
[V03AB36, phentolamine, Phentolamine may increase the orthostatic hypotensive, hypotensive, and antihypertensive activities of Flupentixol.]
[M02AA01, phenylbutazone, The risk or severity of hypertension can be increased when Phenylbutazone is combined with Flupentixol.]
[S01GA05, phenylephrine, The therapeutic efficacy of Phenylephrine can be decreased when used in combination with Flupentixol.]
[R01BA01, phenylpropanolamine, The therapeutic efficacy of Phenylpropanolamine can be decreased when used in combination with Flupentixol.]
[N03AB02, phenytoin, Phenytoin may increase the central nervous system depressant (CNS depressant) activities of Flupentixol.]
[S01AE05, levofloxacin, The risk or severity of QTc prolongation can be increased when Levofloxacin is combined with Flupentixol.]
[C08CX01, mibefradil, The risk or severity of QTc prolongation can be increased when Mibefradil is combined with Flupentixol.]
[N05AG02, pimozide, The risk or severity of QTc prolongation can be increased when Pimozide is combined with Flupentixol.]
[C07AA03, pindolol, Pindolol may increase the orthostatic hypotensive activities of Flupentixol.]
[J05AE01, saquinavir, The risk or severity of QTc prolongation can be increased when Saquinavir is combined with Flupentixol.]
[N05AC04, pipothiazine, Pipotiazine may increase the central nervous system depressant (CNS depressant) activities of Flupentixol.]
[C09CA02, eprosartan, Flupentixol may decrease the antihypertensive activities of Eprosartan.]
[A02BX03, pirenzepine, Flupentixol may increase the central nervous system depressant (CNS depressant) activities of Pirenzepine.]
[N04BC08, piribedil, The therapeutic efficacy of Piribedil can be decreased when used in combination with Flupentixol.]
[N02AC03, pirinitramide, Piritramide may increase the central nervous system depressant (CNS depressant) activities of Flupentixol.]
[S01BC06, piroxicam, The risk or severity of hypertension can be increased when Piroxicam is combined with Flupentixol.]
[J01MA11, grepafloxacin, The risk or severity of QTc prolongation can be increased when Grepafloxacin is combined with Flupentixol.]
[N02CX01, pizotyline, Flupentixol may increase the orthostatic hypotensive, hypotensive, and antihypertensive activities of Pizotifen.]
[C09CA04, irbesartan, Flupentixol may decrease the antihypertensive activities of Irbesartan.]
[N05CA22, proxibarbal, Flupentixol may increase the sedative activities of Proxibarbal.]
[A06AD15, polyethylene glycols, The therapeutic efficacy of Polyethylene glycol can be decreased when used in combination with Flupentixol.]
[A03AE01, alosetron, Alosetron may increase the central nervous system depressant (CNS depressant) activities of Flupentixol.]
[S03AA03, polymyxin B, Flupentixol may increase the neurotoxic activities of Polymyxin B.]
[C03AA05, polythiazide, Flupentixol may decrease the antihypertensive activities of Polythiazide.]
[J05AE03, ritonavir, The risk or severity of QTc prolongation can be increased when Ritonavir is combined with Flupentixol.]
[B05XA01, potassium chloride, The risk or severity of gastrointestinal ulceration can be increased when Flupentixol is combined with Potassium chloride.]
[C07AB01, practolol, Practolol may increase the orthostatic hypotensive activities of Flupentixol.]
[C01BA08, prajmaline, The risk or severity of QTc prolongation can be increased when Prajmaline is combined with Flupentixol.]
[N05BA11, prazepam, Prazepam may increase the central nervous system depressant (CNS depressant) activities of Flupentixol.]
[C02CA01, prazosin, Prazosin may increase the orthostatic hypotensive, hypotensive, and antihypertensive activities of Flupentixol.]
[R06AX05, antazoline, The risk or severity of QTc prolongation can be increased when Antazoline is combined with Flupentixol.]
[C01DX02, prenylamine, The risk or severity of QTc prolongation can be increased when Prenylamine is combined with Flupentixol.]
[N01BB04, prilocaine, Prilocaine may increase the central nervous system depressant (CNS depressant) activities of Flupentixol.]
[P01BA03, primaquine, The risk or severity of QTc prolongation can be increased when Primaquine is combined with Flupentixol.]
[N03AA03, primidone, Flupentixol may increase the sedative activities of Primidone.]
[C10AX02, probucol, The risk or severity of QTc prolongation can be increased when Probucol is combined with Flupentixol.]
[C01BA02, procainamide, The risk or severity of QTc prolongation can be increased when Procainamide is combined with Flupentixol.]
[S01HA05, procaine, Procaine may increase the central nervous system depressant (CNS depressant) activities of Flupentixol.]
[L01XB01, procarbazine, The risk or severity of myelosuppression can be increased when Flupentixol is combined with Procarbazine.]
[N05AB04, prochlorperazine, The risk or severity of QTc prolongation can be increased when Prochlorperazine is combined with Flupentixol.]
[N04AA04, procyclidine, The therapeutic efficacy of Procyclidine can be decreased when used in combination with Flupentixol.]
[N05AA03, promazine, The risk or severity of QTc prolongation can be increased when Promazine is combined with Flupentixol.]
[R06AD02, promethazine, Flupentixol may increase the central nervous system depressant (CNS depressant) activities of Promethazine.]
[C01BC03, propafenone, The risk or severity of QTc prolongation can be increased when Propafenone is combined with Flupentixol.]
[N01AX04, propanidid, Propanidid may increase the central nervous system depressant (CNS depressant) activities of Flupentixol.]
[A03AB05, propantheline, Flupentixol may increase the central nervous system depressant (CNS depressant) activities of Propantheline.]
[N05AC01, periciazine, Flupentixol may increase the orthostatic hypotensive, hypotensive, and antihypertensive activities of Periciazine.]
[N05CM06, propiomazine, Flupentixol may increase the sedative activities of Propiomazine.]
[L01XH02, romidepsin, The risk or severity of QTc prolongation can be increased when Flupentixol is combined with Romidepsin.]
[N01AX10, propofol, Flupentixol may increase the sedative activities of Propofol.]
[N02AC04, propoxyphene, Dextropropoxyphene may increase the central nervous system depressant (CNS depressant) activities of Flupentixol.]
[C07AA05, propranolol, Propranolol may increase the orthostatic hypotensive activities of Flupentixol.]
[H03BA02, propylthiouracil, The risk or severity of myelosuppression can be increased when Flupentixol is combined with Propylthiouracil.]
[N02CC04, rizatriptan, Rizatriptan may increase the central nervous system depressant (CNS depressant) activities of Flupentixol.]
[B01AC09, epoprostenol, Flupentixol may decrease the antihypertensive activities of Epoprostenol.]
[N06AA11, protriptyline, Protriptyline may increase the central nervous system depressant (CNS depressant) activities of Flupentixol.]
[R01BA02, pseudoephedrine, The therapeutic efficacy of Flupentixol can be decreased when used in combination with Pseudoephedrine.]
[N05AX12, aripiprazole, Flupentixol may increase the orthostatic hypotensive, hypotensive, and antihypertensive activities of Aripiprazole.]
[A03AB15, diphemanil, Flupentixol may increase the central nervous system depressant (CNS depressant) activities of Diphemanil.]
[A03AB09, isopropamide, Flupentixol may increase the central nervous system depressant (CNS depressant) activities of Isopropamide.]
[S01FA03, methscopolamine, Flupentixol may increase the central nervous system depressant (CNS depressant) activities of Methscopolamine.]
[N05CA07, talbutal, Flupentixol may increase the sedative activities of Talbutal.]
[N05CA09, vinbarbital, Flupentixol may increase the sedative activities of Vinbarbital.]
[N05BB02, captodiamine, Captodiame may increase the central nervous system depressant (CNS depressant) activities of Flupentixol.]
[M03BA04, styramate, Styramate may increase the central nervous system depressant (CNS depressant) activities of Flupentixol.]
[P02CC01, pyrantel, Pyrantel may increase the central nervous system depressant (CNS depressant) activities of Flupentixol.]
[R06AC01, pyrilamine, Flupentixol may increase the sedative activities of Mepyramine.]
[C01BA01, quinidine, The risk or severity of QTc prolongation can be increased when Quinidine is combined with Flupentixol.]
[P01BC01, quinine, The risk or severity of QTc prolongation can be increased when Quinine is combined with Flupentixol.]
[C02AA01, rescinnamine, Flupentixol may decrease the antihypertensive activities of Rescinnamine.]
[C02AA02, reserpine, Reserpine may increase the central nervous system depressant (CNS depressant) activities of Flupentixol.]
[R03AC05, rimiterol, The therapeutic efficacy of Rimiterol can be decreased when used in combination with Flupentixol.]
[G02CA01, ritodrine, The therapeutic efficacy of Ritodrine can be decreased when used in combination with Flupentixol.]
[N06AX01, 5-hydroxytryptophan, Oxitriptan may increase the central nervous system depressant (CNS depressant) activities of Flupentixol.]
[J01FA06, roxithromycin, The risk or severity of QTc prolongation can be increased when Roxithromycin is combined with Flupentixol.]
[N02BA05, salicylamide, The risk or severity of hypertension can be increased when Flupentixol is combined with Salicylamide.]
[A07EC01, sulfasalazine, The risk or severity of hypertension can be increased when Sulfasalazine is combined with Flupentixol.]
[S01BC08, salicylic acid, The risk or severity of hypertension can be increased when Flupentixol is combined with Salicylic acid.]
[S01FA02, scopolamine, Flupentixol may increase the sedative activities of Scopolamine.]
[N05CA06, secobarbital, Flupentixol may increase the sedative activities of Secobarbital.]
[N04BD01, selegiline, The therapeutic efficacy of Selegiline can be decreased when used in combination with Flupentixol.]
[L01FA03, obinutuzumab, The risk or severity of myelosuppression can be increased when Flupentixol is combined with Obinutuzumab.]
[V04CC01, sorbitol, The therapeutic efficacy of Sorbitol can be decreased when used in combination with Flupentixol.]
[C07AA07, sotalol, The risk or severity of QTc prolongation can be increased when Sotalol is combined with Flupentixol.]
[L01CD04, cabazitaxel, The risk or severity of myelosuppression can be increased when Flupentixol is combined with Cabazitaxel.]
[M01AE11, tiaprofenic acid, The risk or severity of hypertension can be increased when Flupentixol is combined with Tiaprofenic acid.]
[R03BB01, ipratropium bromide, The risk or severity of adverse effects can be increased when Flupentixol is combined with Ipratropium.]
